see your skills in sientra®

# Instructions for use

## SIENTRA SILICONE GEL BREAST IMPLANTS

SMOOTH ROUND,
TEXTURED ROUND AND
TEXTURED SHAPED

The sale and distribution of this device is restricted to users and/or user facilities that provide information to patients about the risks and benefits of this device in the form and manner specified in the approved labeling provided by Sientra, Inc.

**Caution**: Federal (USA) law restricts this device to sale by or on the order of a physician.

**WARNING:**

- Breast implants are not considered lifetime devices. The longer people have them, the greater the chances are that they will develop complications, some of which will require more surgery.
- Breast implants have been associated with the development of a cancer of the immune system called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). This cancer occurs more commonly in patients with textured breast implants than smooth implants, although rates are not well defined. Some patients have died from BIA-ALCL.
- Patients receiving breast implants have reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement.

see your skills in sientra®

Revision Date: January 3, 2023

# TABLE OF CONTENTS


**TABLE OF CONTENTS** . . . . . 4

**INTRODUCTION** . . . . . 8
- DIRECTIONS TO THE PHYSICIAN . . . . . 8
  - Patient Counseling Information . . . . . 8
  - Physician Education . . . . . 9
  - Informed Decision . . . . . 9
  - Device Tracking . . . . . 9
  - Device Identification Card . . . . . 10

**DEVICE DESCRIPTION** . . . . . 11

**INDICATIONS FOR USE** . . . . . 12

**CONTRAINDICATIONS** . . . . . 12

**WARNINGS** . . . . . 12
- MICROWAVE DIATHERMY . . . . . 14

**PRECAUTIONS** . . . . . 14
- SPECIFIC POPULATIONS . . . . . 14
- SURGICAL PRECAUTIONS . . . . . 15
  - Surgical Technique . . . . . 15
  - Implant Selection . . . . . 15
  - Incision Site Selection . . . . . 16
  - Implant Placement Selection . . . . . 16

**INFORMATION TO BE DISCUSSED WITH THE PATIENT** . . . . . 16
- RUPTURE . . . . . 17
- EXPLANTATION . . . . . 17
- REOPERATION . . . . . 18
- BREAST EXAMINATION TECHNIQUES . . . . . 18
- MAMMOGRAPHY . . . . . 18
- LACTATION . . . . . 19
- AVOIDING DAMAGE DURING OTHER TREATMENT . . . . . 19
- SMOKING . . . . . 19
- RADIATION TO THE BREAST . . . . . 19
- INSURANCE COVERAGE . . . . . 19
- MENTAL HEALTH AND ELECTIVE SURGERY . . . . . 20
- LONG-TERM EFFECTS AND POST APPROVAL STUDY . . . . . 20

**GENERAL ADVERSE EFFECTS ASSOCIATED WITH BREAST IMPLANT SURGERY** 20
- RUPTURE . . . . . 21
- CAPSULAR CONTRACTURE . . . . . 22
- REOPERATION . . . . . 23
- IMPLANT REMOVAL . . . . . 23
- PAIN . . . . . 23
- CHANGES IN NIPPLE AND BREAST SENSATION . . . . . 23
- INFECTION . . . . . 23
- UNSATISFACTORY RESULTS . . . . . 24
- BREAST FEEDING COMPLICATIONS . . . . . 24
- ADDITIONAL COMPLICATIONS . . . . . 24

**OTHER REPORTED CONDITIONS** . . . . . 24
- CONNECTIVE TISSUE DISEASE DIAGNOSES OR SYNDROMES . . . . . 25
- CONNECTIVE TISSUE DISEASE SIGNS AND SYMPTOMS . . . . . 26
- CANCER . . . . . 26
  - Breast Cancer . . . . . 26
  - Brain and Nervous System Cancers . . . . . 26
  - Lympho-Hematopoietic Cancers . . . . . 27
  - Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL) . . . . 27
  - Respiratory/Lung Cancer . . . . . 28
  - Reproductive System Cancers . . . . . 28
  - Other Cancers . . . . . 28
- NEUROLOGICAL DISEASE, SIGNS, AND SYMPTOMS . . . . . 29
- MENTAL HEALTH DISORDERS . . . . . 29
- SUICIDE . . . . . 29
- EFFECTS ON CHILDREN . . . . . 29
- POTENTIAL HEALTH CONSEQUENCES OF GEL BLEED . . . . . 30

**SIENTRA'S CLINICAL STUDY** . . . . . 31
- OVERVIEW . . . . . 31
- SUBJECT ELIGIBILITY . . . . . 31
  - Subject Inclusion Criteria . . . . . 31
  - Female . . . . . 31
  - Subject Exclusion Criteria . . . . . 32

STUDY STRENGTHS AND WEAKNESSES ..... 34
PATIENT ACCOUNTING AND DEMOGRAPHICS ..... 34
RUPTURE INFORMATION ON SIENTRA'S IMPLANTS ..... 41
PRIMARY AUGMENTATION AND REVISION-AUGMENTATION PATIENTS ..... 45
PATIENT ACCOUNTING AND FOLLOW-UP RATES ..... 45
EFFECTIVENESS OUTCOMES ..... 45
Primary Augmentation Patients ..... 45
Revision-Augmentation Patients ..... 46
SAFETY OUTCOMES ..... 47
Primary Augmentation Patients ..... 47
Revision-Augmentation Patients ..... 48
REASONS FOR REOPERATION ..... 49
Primary Augmentation Patients ..... 49
Revision-Augmentation Patients ..... 50
REASONS FOR IMPLANT REMOVAL ..... 51
Primary Augmentation Patients ..... 51
Revision-Augmentation Patients ..... 52
OTHER CLINICAL FINDINGS ..... 53
Cancer ..... 53
Connective Tissue Disease ..... 53
CTD Signs and Symptoms ..... 54
Lactation Complications ..... 54
Reproduction Complications ..... 55
Suicide ..... 55
Risk Factor Analysis ..... 55
Primary Augmentation ..... 55
Revision Augmentation ..... 55
PRIMARY RECONSTRUCTION AND REVISION-RECONSTRUCTION PATIENTS ..... 56
PATIENT ACCOUNTING AND FOLLOW-UP RATES ..... 56
EFFECTIVENESS OUTCOMES ..... 56
Primary Reconstruction Patients ..... 56
Revision-Reconstruction Patients ..... 57
SAFETY OUTCOMES ..... 57
Primary Reconstruction Patients ..... 57
Revision-Reconstruction Patients ..... 59
REASONS FOR REOPERATION ..... 61
Primary Reconstruction Patients ..... 61
Revision-Reconstruction Patients ..... 62
REASONS FOR IMPLANT REMOVAL ..... 63
Primary Reconstruction Patients ..... 63
Revision-Reconstruction Patients ..... 63
OTHER CLINICAL FINDINGS ..... 64
Cancer ..... 64
Connective Tissue Disease (CTD) ..... 65
CTD Signs and Symptoms ..... 65
Lactation Complications ..... 65
Reproduction Complications ..... 65
Suicide ..... 66
Other Deaths ..... 66
Risk Factor Analysis ..... 67
Primary Reconstruction ..... 67
Revision-Reconstruction ..... 67
National Breast Implant Registry ..... 67

**INSTRUCTIONS FOR USE ..... 68**
PREOPERATIVE PATIENT PROCEDURES ..... 68
INSTRUCTIONS FOR OPENING AND INSPECTING THE STERILE PACKAGE ..... 68
INTRAOPERATIVE CONSIDERATIONS ..... 69
POSTOPERATIVE CONSIDERATIONS ..... 70

**MANAGING A RUPTURED IMPLANT ..... 70**

**ADDITIONAL PRODUCT-SPECIFIC INFORMATION ..... 70**
RETURNED MERCHANDISE POLICY ..... 70
EXPLANTED DEVICE RETURNS AND REPORTING ..... 71
PRODUCT REPLACEMENT POLICY AND LIMITED WARRANTIES ..... 71
PRODUCT ORDERING ..... 71
ACCESS TO ELECTRONIC INFORMATION ..... 71
REPORTING PROBLEMS ..... 71

**DEVICE MANUFACTURER ..... 72**

**REFERENCES ..... 73**

# INTRODUCTION

## DIRECTIONS TO THE PHYSICIAN

The information contained in this Instructions for Use (IFU) is intended to provide an overview of essential information about Sientra Silicone Gel Breast Implants (also referred to as the "Implants") including a device description, the indications for use, contraindications, warnings, precautions, important factors for a patient to consider, adverse effects, other reported conditions, and a summary of the Sientra Clinical Study of Silicone Gel Breast Implants (also referred to as the "Study"). There is a **Boxed Warning** for all breast implants (See Cover Page).

### Patient Counseling Information

You should review this document and the patient labeling, including the Patient Decision Checklist that highlights key information regarding risks of breast implant surgery, prior to counseling the patient about Sientra Silicone Gel Breast Implants and breast implant surgery. Please familiarize yourself with the content of this document and resolve any questions or concerns prior to proceeding with the use of this device. You should thoroughly review all of the risk information with the patient and address all of her questions prior to signing the Checklist along with the patient, indicating that you have reviewed all of the information and addressed all of her questions. As with any surgical procedure, breast implantation is not without risks. Breast implantation is an elective procedure, and the patient must be well counseled and understand the risk/benefit relationship.

Before making the decision to proceed with surgery, you should instruct the patient to read the document titled: *Patient Educational Brochure*: Breast Augmentation/Reconstruction with Sientra Silicone Gel Breast Implants (patient labeling), and discuss with the patient the warnings, precautions, important factors to consider, complications, and the Study results listed in the patient labeling. You should advise the patient of the potential complications and that medical management of serious complications may include additional surgery and explantation.

Please refer to the *INFORMATION TO BE DISCUSSED WITH THE PATIENT* section of this document for additional patient counseling information.

### Physician Education

Sientra Silicone Gel Breast Implants are available exclusively to board-certified or board-eligible plastic surgeons, who have completed the appropriate training and passed comprehensive written and oral examinations covering all plastic surgery procedures. In order to obtain the credential of Board-Certified Plastic Surgeon, the physician must graduate from an accredited medical school, and complete an additional 5 years (minimum) training as a resident surgeon. The residency training must cover all areas of surgery, including at least 3 years devoted entirely to plastic surgery.

### Informed Decision

Each patient should receive *Sientra's Patient Educational Brochure*: *Breast Augmentation/Reconstruction with Sientra Silicone Gel Breast Implants* during the patient's initial visit/consultation, to allow the patient sufficient time to read and adequately understand the important information on the risks, follow-up recommendations, and benefits associated with silicone gel breast implant surgery.

Allow the patient at least 1-2 weeks to review and consider this information before deciding to have primary breast surgery. In the case of revision surgery, it may be advisable to perform surgery sooner.

In order to document a successful informed decision process, as discussed above the patient labeling includes a *Patient Decision Checklist*, which should be signed by both the patient and the surgeon and then retained in the patient's file. A copy should also be provided to the patient.

### Device Tracking

Silicone Gel Breast Implants are subject to device tracking per Food and Drug Administration (FDA) regulation. Tracking is intended to facilitate notifying patients in the event that important new information about a device becomes available. The laws that govern device tracking require physicians to report certain information relating to their practice, the breast implants used, and the patients who receive breast implants (21 CFR §821.30).[1] A physician prescribing Silicone Gel Breast Implants is required, by federal regulation, to comply with Device Tracking Regulations, and report to Sientra:

- The serial number of the implanted device(s),

- The date of the implant surgery,
- Patient's name,
- The patient's personal contact information (including address, telephone number and date of birth),
- Contact information for the prescribing physician's practice and the physician who regularly sees the patient for primary care, and
- (When applicable) the date the device was:
  - Explanted, with the name, mailing address, and telephone number of the explanting physician;
  - Out of use due to patient death (date of death);
  - Returned to the manufacturer;
  - Permanently disposed of.

Tracking continues until the implant is returned, destroyed, explanted, or the patient becomes deceased. Tracking information will be recorded on the **Device Tracking Form** supplied by Sientra with each Implant. The form should then be returned to Sientra via email to enrollment@sientra.com or fax to (888) 906-0101. The privacy and security of providers and patients is safeguarded through the use of email transmission encryption technologies.

Sientra strongly recommends that all patients receiving Sientra's Implants participate in Sientra's Device Tracking program.

Patients are not required by law to enroll themselves in any tracking program or device registry. However, participation in Sientra's Device Tracking program is required in order to activate the Sientra Limited Warranty discussed in the *PRODUCT REPLACEMENT POLICY AND LIMITED WARRANTIES* section of this IFU. Patients must allow their physicians to share contact information and information about the implant in order to activate the Warranty.

## Device Identification Card

Each patient should receive their own Device Identification Card. Before giving the patient their card, make sure it has all the details of their implant(s) on it. Inform the patient to keep their Device Identification Card for their medical records. Please see Section 16 of the Patient Educational Brochures for more information about the Device Identification Card.



# DEVICE DESCRIPTION

Sientra Implants are single-lumen devices composed of a barrier-type, silicone elastomer shell, filled with high-strength silicone gel. The Implants are dry heat sterilized and are available in various shapes, profiles, and sizes.

Table 1. shows available styles and sizes of Sientra's Silicone Gel Breast Implants.

**Table 1. Sientra Silicone Gel Breast Implant Designs**

| Style Number and Gel Filler | | Shell Surface | Shape and Profile | Volume (cc) | Width (cm) | Height (cm) | Projection (cm) |
|---|---|---|---|---|---|---|---|
| HSC | HSC+ | | | | | | |
| 10512-MP | 10712-MP | Smooth | Round Moderate | 80-700 | 8.1-16.1 | 8.1-16.1 | 2.1-4.7 |
| 10521-HP | 10722-HP | Smooth | Round High | 95-695 | 8.2-15.4 | 8.2-15.4 | 2.5-4.9 |
| 20612-MP | 20712-MP | Textured | Round Moderate | 80-700 | 8.1-16.1 | 8.1-16.1 | 2.1-4.7 |
| 10610-LP | 10710-LP | Smooth | Round Low | 60-700 | 7.3-17.9 | 7.3-17.9 | 2.1-3.8 |
| 20610-LP | 20710-LP | Textured | Round Low | 60-700 | 7.3-17.9 | 7.3-17.9 | 2.1-3.8 |
| 10610-LPP | 10710-LPP | Smooth | Round Low Plus | 80-440 | 8.0-14.5 | 8.0-14.5 | 2.1-3.9 |
| 10621-MP/HP | 10721-MP/HP | Smooth | Round Moderate/High | 95-700 | 7.7-15.1 | 7.7-15.1 | 2.9-6.0 |
| 10621-XP | 10721-XP | Smooth | Round Extra High | 190-510 | 8.75-12.0 | 8.75-12.0 | 4.6-6.2 |
| 20621-MP/HP | 20721-MP/HP | Textured | Round Moderate/High | 95-700 | 7.7-15.1 | 7.7-15.1 | 2.9-6.0 |
| 20621-XP | 20721-XP | Textured | Round Extra High | 190-510 | 8.75-12.0 | 8.75-12.0 | 4.6-6.2 |
| N/A | 20645-LP OBASE | Textured | Shaped Oval Base Low | 170-700 | 11.3-17.4 | 9.8-14.9 | 2.8-4.5 |
| N/A | 20645-MP/HP OBASE | Textured | Shaped Oval Base Moderate/High | 120-700 | 8.9-16.9 | 8.0-14.5 | 3.4-6.2 |
| N/A | 20646-RB (MP) RBASE | Textured | Shaped Round Base Moderate | 160-700 | 9.2-15.5 | 9.2-15.5 | 4.0-6.1 |
| N/A | 20646-RB (HP) RBASE | Textured | Shaped Round Base High | 180-550 | 9.8-14.6 | 8.3-13.4 | 4.3-6.2 |
| N/A | 20676-E (MP) CBASE | Textured | Shaped Classic Base Moderate | 115-700 | 8.0-16.1 | 9.0-17.2 | 3.2-5.8 |
| N/A | 20676-E (HP) CBASE | Textured | Shaped Classic Base High | 190-635 | 9.0-14.0 | 10.0-15.0 | 4.2-6.2 |

## INDICATIONS FOR USE

Sientra Silicone Gel Breast Implants are indicated for:

- **Breast augmentation for women at least 22 years old.** Breast augmentation includes primary breast augmentation as well as revision surgery to correct or improve the result of primary breast augmentation surgery.
- **Breast reconstruction.** Breast reconstruction includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. Breast reconstruction also includes revision surgery to correct or improve the results of a primary breast reconstruction surgery.

## CONTRAINDICATIONS

Breast implant surgery is contraindicated in women

- With active infections anywhere in their body,
- With existing cancer or precancerous conditions who have not received adequate treatment for those conditions,
- Who are currently pregnant or nursing.

## WARNINGS

AVOID DAMAGING THE IMPLANT DURING SURGERY AND OTHER MEDICAL PROCEDURES

**WARNING**

- **Breast implants are not considered lifetime devices. The longer people have them, the greater the chances are that they will develop complications, some of which will require more surgery.**
- **Breast implants have been associated with the development of a cancer of the immune system called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). This cancer occurs more commonly in patients with textured breast implants than smooth implants, although rates are not well defined. Some patients have died from BIA-ALCL.**
- **Patients receiving breast implants have reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement.**

The most common causes of implant rupture include damage to the implant that occurs during the surgical implantation or other related medical procedures. Accordingly, physicians should not use excessive force and should minimize the handling of the implant during surgical insertion.

- Do not allow cautery devices or sharp instruments, such as scalpels, suture needles, hypodermic needles, hemostats, Adson forceps or scissors to contact the Implant during the implantation procedures.
- Use an appropriate length incision to accommodate the style, size, and profile of the implant.
- Do not treat capsular contracture by closed capsulotomy or forceful external compression, which could likely result in implant damage, rupture, folds, and/or hematoma.
- Use care in subsequent procedures, such as open capsulotomy, breast pocket revision, hematoma/seroma aspiration, and biopsy/lumpectomy to avoid damage to the implant. Repositioning of the implant during surgical procedures should be carefully evaluated by the medical team and care taken to avoid contamination of the implant. Use of excessive force during any subsequent procedure can contribute to localized weakening of the breast implant shell potentially leading to decreased device performance.

- Do not immerse the implant in any liquid such as Betadine or other iodine solution. If Betadine is used in the pocket, ensure that it is rinsed thoroughly so that no residual solution remains in the pocket.
- Do not alter the implants or attempt to repair or insert a damaged implant.
- Do not reuse or re-sterilize any implant that has been previously implanted. Breast implants are intended for single use only.
- Do not place more than one implant per breast.
- Do not use the periumbilical approach to place this implant.

### MICROWAVE DIATHERMY

Do not use microwave diathermy in patients with breast implants, as it has been reported to cause tissue necrosis, skin erosion, and implant extrusion.

## PRECAUTIONS

### SPECIFIC POPULATIONS

The safety and effectiveness of this device have not been established in patients with

- Autoimmune diseases, for example, Lupus and Scleroderma,
- A compromised immune system (for example, currently receiving immunosuppressive therapy),
- Conditions or medications that interfere with wound healing and blood clotting,
- Reduced blood supply to breast tissue,
- Planned chemotherapy following breast implant placement,
- Planned radiation therapy to the breast following breast implant placement,
- History of radiation therapy to the breast,
- Clinical diagnosis of depression or other mental disorders, including body dysmorphic disorder and eating disorders. Please discuss any history of mental health disorders with your patient prior to surgery. Patients with a diagnosis of depression or other mental disorders should wait until resolution or stabilization of these conditions prior to undergoing breast implantation surgery.



In order to avoid possible injury or damage to the incision site(s), you should advise your patients to avoid the following for the first month after the surgery:

- Sun exposure,
- Jerky movements or activities that stretch the skin at your incision site(s),
- Participating in sports or other activities that raise your pulse or blood pressure, and
- Unnecessary physical or emotional stress.

### SURGICAL PRECAUTIONS

Surgical precautions, such as those described below, should be undertaken to maximize a successful aesthetic result and the long-term performance of the device.

#### Surgical Technique

The implantation of Sientra Silicone Gel Breast Implants involves a variety of surgical techniques. Therefore, you should use the method, which in your own best medical judgment, will provide the patient with the desired outcome consistent with this *Instructions for Use* document.

#### Implant Selection

In to properly select the correct implant, the following considerations should be taken into account and, as appropriate, discussed with the patient:

- The implant should be consistent in size with the patient's chest-wall dimensions, including base width measurements, also considering the laxity of the tissue and the projection of the implant.
- A thorough discussion should be conducted with the patient, employing appropriate visual aids to clarify her objectives and manage expectations, in order to reduce the incidence of reoperation for size change.
- The following may cause implants to be more palpable: larger implants, subglandular placement, and an insufficient amount of skin/tissue available to cover the implant.
- Available tissue must provide adequate coverage of the implant.

### Incision Site Selection

You should choose one of the following incision sites, based on your patient's particular needs:

- The periareolar incision
- The inframammary incision
- The axillary incision

The periareolar incision is typically more concealed; however, it may be associated with an increased risk of certain complications, such as changes in breast sensation and difficulties breastfeeding, as compared to other incision sites (2000).[2]

The periumbilical approach has not been studied in Sientra's Study and should not be used for a variety of reasons, including potential damage to the implant shell.

### Implant Placement Selection

A well-defined, dry pocket of adequate size and symmetry must be created for implant placement.

Possible benefits of submuscular placement are that it may result in less palpable implants, less likelihood of capsular contracture (2000)[2], and easier imaging of the breast for mammography. Also, submuscular placement may be preferable if the patient has thin or weakened breast tissue.

Subglandular placement may result in more palpable implants, greater likelihood of capsular contracture (2004-2005),[3, 4] and increased difficulty in imaging the breast with mammography.

## INFORMATION TO BE DISCUSSED WITH THE PATIENT

Breast implantation is an elective procedure, and the patient must be thoroughly counseled on the risks, as well as the benefits, of these products and procedures. You should advise your patient that she must read the patient labeling for either augmentation or reconstruction, as applicable. The patient labeling is intended as the primary means to relate uniform risk and benefit information to assist your patient in making an informed decision about primary breast augmentation and revision-augmentation, or primary reconstruction and revision-reconstruction surgery (as applicable), but is not intended to replace consultation with you. The patient should be advised to wait at least 1-2 weeks after reviewing and considering this information before deciding whether to have this surgery unless an earlier surgery is deemed medically necessary.

Both you and your patient will be required to sign the *Patient Decision Checklist* form prior to surgery. This form can be found on the last page of each patient brochure. The form, once signed, acknowledges the patient's full understanding of the information provided in the brochure. The form should be retained in the patient's permanent medical record.

Below are some of the important factors your patients need to be aware of when using Sientra Implants.

### RUPTURE

Rupture of a silicone gel breast implant may be silent/asymptomatic (i.e., there are no symptoms experienced by the patient and no physical signs of changes with the implant), rather than symptomatic. You should advise your patient to undergo regular breast ultrasound or magnetic resonance imaging (MRI) to screen for silent rupture even if she is asymptomatic. For asymptomatic patients, the first ultrasound or MRI should be performed at 5-6 years postoperatively, then every 2-3 years thereafter. For symptomatic patients or patients with equivocal ultrasound results for rupture at any time postoperatively, an MRI is recommended. If rupture is noted on imaging, then you should advise your patient to have her Implant removed. You should provide her with a list of MRI facilities in her area that have at least a 1.5 Tesla magnet, a dedicated breast coil, and a radiologist experienced with reading breast implant MRIs to diagnose a silent rupture. Diagnostic procedures will add to the cost of having implants, and patients should be aware or advised that these costs may exceed the cost of their initial surgery over their lifetime and that their insurance carrier may not cover these costs.

### EXPLANTATION

Implants are not considered lifetime devices, and patients will likely undergo implant removal(s), with or without replacement, over the course of their life. When implants are removed without replacement, changes to the patient's breasts may be irreversible. Complication rates are typically higher following revision surgery (removal with replacement).

## REOPERATION

Additional surgeries to the patient's breasts will likely be required, whether because of implant rupture, other complications, or unacceptable size/cosmetic outcomes. Patients should be advised that their risk of future complications increases with revision surgery as compared to primary augmentation or reconstruction surgery. Further, in a reoperation in which the implant is not removed (such as open capsulotomies or scar revision), there is a risk that the integrity of the implant's shell could be compromised inadvertently, potentially leading to product failure.

## BREAST EXAMINATION TECHNIQUES

Patients should perform breast self-examinations monthly and be shown how to distinguish the implant from their breast tissue. The patient should not manipulate or squeeze the implants excessively. The patient should be told that the presence of lumps, persistent pain, swelling, hardening, or change in the implant shape might be symptoms of rupture of the implant. If the patient has any of these signs, the patient should be told to report them to her surgeon, and possibly have an MRI evaluation to screen for rupture.

## MAMMOGRAPHY

Patients who have undergone augmentation or revision augmentation should be instructed to undergo routine mammography exams as per their physician's recommendations. Mammograms may not be appropriate for all patients undergoing reconstruction. Please instruct the patient to consult with her surgeon or oncologist for mammogram recommendations specific to her situation. The importance of having these exams should be emphasized. Patients should be instructed to inform their mammography technologist about the presence, type, and placement of their implants. Patients should request a diagnostic mammography, rather than a screening mammography, because more pictures are taken with diagnostic mammography. Breast implants may complicate the interpretation of mammographic images by obscuring underlying breast tissue and/or by compressing overlying tissue. Accredited mammography centers, technicians with experience in imaging patients with breast implants, and the use of displacement techniques, are needed to adequately visualize breast tissue in the implanted breast. The current recommendations for preoperative/screening mammograms are no different for women with breast implants than for those women without implants. Pre-surgical mammography with a follow-up mammogram after implantation may be performed to establish a baseline for routine future mammography in augmentation patients.

## LACTATION

Breast implant surgery may interfere with the ability to successfully breast feed, either by reducing or eliminating milk production. The Institute of Medicine (IOM), in its 1999 report on the safety of silicone breast implants, encourages mothers with silicone gel breast implants to breast feed, stating that while breast implantation may increase the risk of lactation difficulties, there is no evidence of a hazard to the infant "beyond the loss of breastfeeding itself", (2000).[2] Other professional medical associations and independent scientific panels have echoed these conclusions and recommendations (1996,1998, 2001).[5-7]

## AVOIDING DAMAGE DURING OTHER TREATMENT

Patients should inform other treating physicians of the presence of implants to minimize the risk of damage to the implants.

## SMOKING

As with any surgery, smoking may interfere with the healing process after breast implant surgery.

## RADIATION TO THE BREAST

Sientra has not tested the *in vivo* effects of radiation therapy in patients who have breast implants. The literature suggests that radiation therapy may increase the likelihood of capsular contracture (2006,2009),[8, 9] necrosis, and implant extrusion (2009).[10]

## INSURANCE COVERAGE

Patients should be advised that health insurance premiums may increase, insurance coverage may be dropped, and/or future coverage may be denied based on the presence of breast implants. Treatment of complications of breast implantation may not be covered as well. Patients should check with their insurance company regarding coverage issues before undergoing surgery.

## MENTAL HEALTH AND ELECTIVE SURGERY

It is important that all patients seeking to undergo elective surgery have realistic expectations that focus on improvement rather than perfection.

Request that your patient openly discuss with you, prior to surgery, any history that she may have of depression or other mental health disorders.

## LONG-TERM EFFECTS AND POST APPROVAL STUDY

Sientra has completed its 10-year Silicone Gel Breast Implant Clinical Study (referred to as "Sientra's Clinical Study" or "The Study") and the reported 10-year data is presented within this IFU, see Section *Sientra's Clinical Study Overview* for additional information.

Sientra currently has another post approval clinical study (U.S. Post Approval Study, "US PAS") on-going to evaluate the long-term clinical performance of Sientra's implants under general conditions of use in the post-market environment. The primary endpoints in Sientra's US PAS post approval study include long-term local complications, connective tissue disease (CTD), CTD signs and symptoms, neurological disease, neurological signs and symptoms, offspring issues, reproductive issues, lactation issues, cancer, including Breast-Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), suicide, mammography issues, and MRI compliance and results. Sientra will continue to update its product labeling on a regular basis with the results of the ongoing U.S. Post Approval Study. It is important for you to relay any new safety information to your patients as soon as such information is provided to you.

# GENERAL ADVERSE EFFECTS ASSOCIATED WITH BREAST IMPLANT SURGERY

Potential adverse events that may occur with silicone gel breast implant surgery include rupture, capsular contracture, reoperation, implant removal, pain, changes in nipple and breast sensation, infection, hematoma/seroma, unsatisfactory results, breast feeding complications and additional complications.

Below is a description of these adverse events. For specific adverse event rates/outcomes for Sientra Implants, refer to the Study section that follows.

## RUPTURE

Breast implants are not lifetime devices. Breast implants rupture when the shell develops a tear or hole. Rupture can occur any time after implantation, but rupture is more likely to occur the longer the implant is implanted. The following things may cause implants to rupture: damage by surgical instruments; stressing the implant during implantation and weakening it; folding or wrinkling of the implant shell; excessive force to the chest; trauma; compression during mammographic imaging; and severe capsular contracture. Breast implants may also simply wear out over time.

Silicone gel breast implant ruptures may be silent. This means that it is possible that neither you nor your patient will know if the implant has ruptured. Asymptomatic patients should have their first ultrasound or magnetic resonance imaging (MRI) performed at 5-6 years postoperatively, then every 2-3 years thereafter. Symptomatic patients or patients with equivocal ultrasound results for rupture at any time postoperatively, an MRI is recommended.

Studies (1992,1995-1996) in the medical literature suggest that silent rupture is relatively uncommon.[11-13] Rupture rates appear to be higher following primary or revision reconstruction than primary or revision augmentation, as seen in the Sientra CORE Clinical Study (10-year). In some instances, gel may migrate from the implant into the capsule and possibly outside of the capsule to other places in the body. Sometimes there are local symptoms associated with gel implant rupture. These symptoms include hard knots or lumps surrounding the implant or in the armpit, change or loss of size or shape of the breast or implant, pain, tingling, swelling, numbness, burning, or hardening of the breast (2001-2003).[14-17]

When MRI findings indicate a rupture (such as subcapsular lines, characteristic folded wavy lines, teardrop sign, keyhole sign, noose sign), or there are ultrasound findings of rupture or if there are signs or symptoms of rupture, you should remove the Implant (with or without replacement of the Implant) and any gel you determine is present. It also may be necessary to remove the tissue capsule, as well, all of which will involve additional surgery, with associated costs. If your

patient has symptoms, such as breast hardness, a change in breast shape or size, and/or breast pain, you should recommend that she have an MRI to determine whether rupture is present (2000, 2004).[2, 18]

There may also be consequences of rupture. If rupture occurs, silicone may either remain within the scar tissue surrounding the Implant (intracapsular rupture) or move outside the capsule (extracapsular rupture), or gel may move beyond the breast (migrated gel). There is also a possibility that rupture that initially occurs as an intracapsular rupture may progress to extracapsular and beyond. There have been few health consequences associated with migrated gel reported in the literature.

**Additional Information on the Consequences of Rupture from Literature:**

Studies of Danish women evaluated with MRI involving a variety of manufacturers and implant models showed that about three-fourths of implant ruptures are intracapsular and the remaining one-fourth is extracapsular (2001)[19]. Additional studies of Danish women indicate that over a 2-year period, about 10% of the implants with intracapsular rupture progressed to extracapsular rupture as detected by MRI (2004).[18] Approximately half of the women whose ruptures had progressed from intracapsular to extracapsular reported that they experienced trauma to the affected breast during this time period or had undergone mammography. In the other half, no cause was given. In the women with extracapsular rupture, after 2 years, the amount of silicone seepage outside the scar tissue capsule increased for about 14% of these women. This type of information pertains to a variety of silicone implants from a variety of manufacturers and implant models and is not specific to Sientra's Silicone Gel Breast Implants.

## CAPSULAR CONTRACTURE

Patients should be advised that capsular contracture might be more common following infection, hematoma, and seroma, and that the chance of it occurring may increase over time. Capsular contracture is also a risk factor for implant rupture (2001),[15] and it is one of the most common reasons for reoperation. Patients should be advised that additional surgery might be needed in cases where pain and/or firmness are severe. This surgery ranges from removal of the implant capsule tissue to removal and possible replacement of the implant itself. This surgery may result in loss of breast tissue. Capsular contracture may recur after these additional surgeries.



## REOPERATION

Patients should be advised that additional surgery to their breast and/or implant will likely be necessary over the course of their life. Reoperations can be required for many reasons including a patient's decision to change the size or type of her implants, or to otherwise improve her breast surgery outcome.

## IMPLANT REMOVAL

Patients should be advised that the implants are not considered lifetime devices and they will potentially undergo Implant removal, with or without replacement, over the course of their life. Patients should also be advised that the changes to their breast following explantation might be irreversible.

## PAIN

Pain of varying intensities and lengths of time may occur and persist following breast implant surgery. In addition, improper size, placement, surgical technique, or capsular contracture may result in pain. The surgeon should instruct his or her patient to inform him or her if there is significant pain or if pain persists.

## CHANGES IN NIPPLE AND BREAST SENSATION

Sensation in the nipple and breast can increase or decrease after implant surgery.

Sensation is typically lost after complete mastectomy where the nipple itself is removed. This loss of feeling can be severely lessened by partial mastectomy. Radiation therapy also can significantly reduce sensation in the remaining portions of the breast or chest wall. The placement of breast implants for reconstruction may further lessen the sensation in the remaining skin or breast tissue. The range of changes varies from intense sensitivity to no feeling in the nipple or breast following surgery. While some of these changes can be temporary, they can also be permanent, and may affect the patient's sexual response or ability to breast feed.

## INFECTION

In rare instances, acute infection may occur in a breast with implants. The signs of acute infection include erythema, tenderness, fluid accumulation, pain, and fever. Very rarely, Toxic Shock Syndrome, a

potentially life-threatening condition, has been reported in women after breast implant surgery. It is characterized by symptoms that occur suddenly and include high fever (102°F, 38.8°C), vomiting, diarrhea, a sunburn-like rash, red eyes, dizziness, lightheadedness, muscle aches, and drops in blood pressure, which may cause fainting. Patients should be instructed to contact a physician immediately for diagnosis and treatment for any of these symptoms.

### UNSATISFACTORY RESULTS

Patients should be informed that dissatisfaction with cosmetic results related to such things as incorrect size, scar deformity, hypertrophic scarring, capsular contracture, asymmetry, wrinkling, implant displacement/migration, and implant palpability/visibility might occur. Careful surgical planning or technique can minimize, but not preclude the risk of such results. Pre-existing asymmetry may not be entirely correctable. Revision surgery may be indicated to maintain patient satisfaction but carries additional considerations and risks.

### BREAST FEEDING COMPLICATIONS

Difficulties with breast-feeding have been reported following both breast reduction and breast augmentation surgeries. A periareolar surgical approach may further increase the chance of breast-feeding difficulties.

### ADDITIONAL COMPLICATIONS

After breast implant surgery, the following may occur and/or persist, with varying intensity and/or varying length of time: implant extrusion, necrosis, delayed wound healing, and breast tissue atrophy/chest wall deformity. Calcium deposits can form in the tissue capsule surrounding the implant with symptoms that may include pain and firmness. Lymphadenopathy has also been reported in some women with implants.

## OTHER REPORTED CONDITIONS

Patients receiving breast implants have reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement.



There have been reports in the literature of other conditions in women with silicone gel breast implants. Many of these conditions have been studied to evaluate their potential association with breast implants. Furthermore, there is the possibility of risks, yet unknown, which in the future could be determined to be associated with breast implants. It should be noted that the cited references include data from augmentation and/or reconstruction patients, as well as from a variety of manufacturers and implant models. The following information was obtained from literature published through the end of 2020.

### CONNECTIVE TISSUE DISEASE DIAGNOSES OR SYNDROMES

Connective tissue diseases include diseases such as lupus, scleroderma, rheumatoid arthritis, and fibromyalgia. There have been a number of published epidemiological studies, meta-analyses, and "weight-of-the-evidence" or critical reviews that have looked at whether having a breast implant is associated with having a typical or defined connective tissue disease. The study size needed to conclusively rule out a smaller risk of connective tissue disease among women with silicone gel breast implants would need to be very large (2000, 2003-2004).[2, 22-27] These published studies (1997-2002, 2004,2016,2019) taken together show that breast implants are either not significantly associated with a risk of developing a typical or defined connective tissue disease, or if a significance was detected, based on limitations of the studies a causative relationship with breast implants could not be determined.[2, 14, 15, 24-26, 28-38] These studies do not distinguish between women with intact and ruptured implants. One study (2003) evaluated specific connective tissue disease diagnoses and symptoms in women with silent ruptured versus intact implants, but it was too small to rule out a small risk.[23] Another study(2003) in a small group of women concluded that significantly more women with ruptured implants than intact implants reported debilitating chronic fatigue;[39] the women reported their symptoms after learning whether or not they had a ruptured implant.

Some independent scientific panels and review groups have concluded that there is no evidence to support an association between breast implants and connective tissue disease (2011),[42] or at least, if a risk cannot be absolutely excluded it is too small to be quantified (1998 and 2000-2001).[2, 7, 26]

## CONNECTIVE TISSUE DISEASE SIGNS AND SYMPTOMS

Some literature reports have also been made associating silicone gel breast implants with various rheumatological signs and symptoms, such as fatigue, exhaustion, joint pain and swelling, muscle pain and cramping, tingling, numbness, weakness, and skin rashes. Having these rheumatological signs and symptoms does not necessarily mean that a patient has a connective tissue disease. Some scientific expert panels (2000) and literature reports (2001-2002 and 2004) have found no evidence of a consistent pattern of signs and symptoms in women with silicone gel breast implants.[2, 43-46] If a patient has an increase in these signs or symptoms, you should refer her to a rheumatologist to determine whether these signs or symptoms are due to a connective tissue disorder or autoimmune disease.

Patients receiving breast implants have reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement.

## CANCER

### Breast Cancer

Some reports (2000-2001,2006-2007,2015) in the medical literature indicate that patients with breast implants are not at a greater risk than those without breast implants for developing breast cancer.[29, 47-56] Some reports (2000,2002-2004,2019) have suggested that breast implants may interfere with or delay breast cancer detection by mammography and/or biopsy; however, other reports in the published medical literature indicated that breast implants neither significantly delay breast cancer detection nor adversely affect cancer survival of women with breast implants.[23, 47, 50, 55, 57-59]

### Brain and Nervous System Cancers

One study has reported an increased risk of brain cancer in women with breast implants as compared to the general population (2001).[48] The incidence of brain cancer, however, was not significantly increased in women with breast implants when compared to women who had other types of plastic surgeries; the study relied on very few cases and the authors relied upon death certificates for brain cancer diagnoses, which may reflect other cancers that have metastasized.



Other large studies (2000, 2002, 2004, 2006-2007,2009,2012,2017) and a published review of four large studies in women with cosmetic implants concluded that the evidence does not support an association between brain cancer and breast implants.[25, 49, 51-55, 60][41, 61]

### Lympho-Hematopoietic Cancers

One study (2001) has reported an increased risk of leukemia in women with breast implants as compared to the general population.[48] However, there was no increased risk when compared to women who had other types of plastic surgery. Other recent large studies (2000, 2002, 2004, 2006-2007,2009,2012) concluded that the evidence does not support an association between lympho-hematopoietic cancers and breast implants.[25, 49, 51-55, 60, 61]

### Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL)

Based on information reported to global regulatory agencies and found in medical literature, an association has been identified between breast implants and the development of anaplastic large cell lymphoma (BIA-ALCL), a type of non-Hodgkin's lymphoma (2008).[62] Women with breast implants have a very small but increased risk of developing ALCL (BIA-ALCL) in the fluid or scar capsule adjacent to the implant., with documented potential for local, regional, and distant spread of the cancer with mortality reported in rare cases.

BIA-ALCL has been reported globally in patients with an implant history that includes Sientra's and other manufacturers' breast implants with various surface properties, styles, and shapes. Most of the cases in the literature reports describe a history of the use of textured implants.

You should consider the possibility of BIA-ALCL when a patient presents with late onset, persistent peri-implant seroma. In some cases, patients presented with capsular contracture or masses adjacent to the breast implant. When testing for BIA-ALCL, collect fresh seroma fluid and representative portions of the capsule, and send to a laboratory with appropriate expertise for pathology tests to rule out BIA-ALCL, including immunohistochemistry testing for CD30 and ALK (anaplastic lymphoma kinase). If your patient is diagnosed with peri-implant BIA-ALCL, develop an individualized treatment plan in coordination with a multidisciplinary care team. Because of the small number of cases worldwide, there is no worldwide consensus on the treatment regimen for peri-implant BIA-ALCL. However, the National

Comprehensive Cancer Network (NCCN) recommends surgical treatment that includes implant removal and complete capsulectomy ipsilaterally as well as contralaterally, where applicable

Report all confirmed cases of BIA-ALCL to the FDA (https://www.fda.gov/Safety/MedWatch/). In some cases, the FDA may contact you for additional information. The FDA will keep the identities of the reporter and the patient confidential.

FDA also recommends reporting cases of BIA-ALCL to the PROFILE Registry (https://www.thepsf.org/research/clinical-impact/profile.htm) where you can submit more comprehensive case data. This will help provide a better understanding of the etiology of BIA-ALCL.

For additional information on FDA's analysis and review of the BIA-ALCL please visit: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239995.htm

### Respiratory/Lung Cancer

One study (2001) has reported an increased incidence of respiratory/lung cancer in women with breast implants.[48] Other research (2006) in women in Sweden and Denmark have found that women who get breast implants are more likely to be current smokers than women who get breast reduction surgery or other types of cosmetic surgery.[53] Several large studies (2002, 2006-2007, 2009, 2012) have found no association between breast implants and respiratory/lung cancer.[49, 51, 52, 54, 55, 60, 61]

### Reproductive System Cancers

One study (2001) has reported an increased incidence of cervical/vulvar cancer in women with breast implants.[48] However, there was no increased risk when compared to women who had other types of plastic surgery. Another study (2007) reported an increased incidence of vulvar cancer that has not been explained.[51] Other recent large studies (2000, 2002, 2004, 2006, 2009, 2012, 2017) concluded that the evidence does not support an association between reproductive system cancers and breast implants.[25, 49, 52-55][41, 60, 61]

### Other Cancers

There have been several studies published that examined the risk of other types of cancers, e.g., thyroid cancers, urinary system cancers, sarcoma, endocrine cancer, connective tissue cancer, cancer of the eye, and unspecified cancers in women with breast implants. All of those studies found no increased risk in women with breast implants (2000-2001, 2003-2004, 2006-2007, 2009, 2012).[17, 44, 48, 49, 51-54, 60, 61]

## NEUROLOGICAL DISEASE, SIGNS, AND SYMPTOMS

Some women with breast implants have complained of neurological symptoms (such as difficulties with vision, sensation, muscle strength, walking, balance, thinking, or remembering things) or neurological diseases (such as multiple sclerosis), which they believe are related to their implants. One scientific expert panel(2000) found that the evidence for a neurological disease or syndrome caused by or associated with breast implants is insufficient or flawed.[2] Subsequent to that report, one epidemiological study (2001)[96] and one cohort study (2001)[29] examined a variety of neurological diseases in women with breast implants and found no significantly increased risk.

## MENTAL HEALTH DISORDERS

Patients should be encouraged to discuss any history of mental health disorders, including a clinical diagnosis of depression, body dysmorphic disorder or eating disorder with you during their consultation visit(s). Patients with a diagnosis of depression or other mental health disorder should be encouraged to wait to schedule surgery until these conditions resolve.

## SUICIDE

In several studies and a systematic review (2001-2004, 2010,2016), a higher incidence of suicide, depression, and/or anxiety was observed in women with breast implants.[97-103] The reason for the observed increase is unknown, but in one study it was found that women with breast implants had higher rates of hospital admissions due to psychiatric causes prior to surgery, as compared with women who had breast reduction or in the general population of Danish women.[99]

## EFFECTS ON CHILDREN

It is not known if a small amount of silicone may pass through from the breast implant silicone shell into breast milk during breast-feeding. Although there are no current established methods for accurately detecting silicone levels in breast milk, a study (2000) measuring silicon (one component of silicone) levels did not indicate higher levels in breast milk from women with silicone gel breast implants when compared to women without implants (based on literature published from 2000.[104]

In addition, concerns have been raised regarding potential damaging effects on children born to mothers with implants. Several studies (2001-2002, 2006 ) in humans have found that the risk of birth defects or other adverse health effects overall is not increased in children born after breast implant surgery.[109-111] Although low birth weight was reported in one study (2004), other factors (for example, lower pre-pregnancy weight) may explain this finding.[112] This author recommended further research on infant health.

## POTENTIAL HEALTH CONSEQUENCES OF GEL BLEED

Small quantities of low molecular weight (LMW) silicone compounds, as well as platinum (in zero oxidation state), have been found to diffuse ("bleed") through an intact implant shell (2000, 2003).[2, 113] The evidence is inconclusive as to whether there are any clinical consequences associated with gel bleed. For instance, studies on implanted women over a long duration have suggested that such bleed may be a contributing factor in the development of capsular contracture (2000)[2] and lymphadenopathy (2005, 2016).[114][115] However, evidence against gel bleed being a significant contributing factor to capsular contracture and other local complications, is provided by the fact that there are similar or lower complication rates for silicone gel breast implants than for saline-filled breast implants. Saline-filled breast implants do not contain silicone gel, and, therefore, gel bleed is not an issue for those products. Furthermore, toxicology testing has indicated that the silicone material used in the Study implants does not cause toxic reactions when large amounts are administered to test animals. It should also be noted that studies reported in the literature have demonstrated that the low concentration of platinum contained in breast implants is in the zero oxidation (most biocompatible) state (1987, 1995, 1999).[116-119]

Sientra performed a laboratory test to analyze the silicones and platinum (used in the manufacturing process), which may bleed out of intact implants into the body. Over 99% of the LMW silicones and platinum stayed in the implant. The overall body of available evidence supports that the extremely low level of gel bleed is of no clinical consequence.



# SIENTRA'S CLINICAL STUDY

## OVERVIEW

Silicone Gel Breast Implant Clinical Study (called the "Study") is a prospective, 10-year, multicenter clinical study conducted to examine the safety and effectiveness of Sientra's Silicone Gel Breast Implant in patients undergoing primary augmentation, primary reconstruction, revision-augmentation, and revision-reconstruction of the breast. The Study consists of data from the primary augmentation and revision-augmentation cohorts of Sientra's CORE study, as well as pooled data from Sientra's CORE and Continued Access (CA) studies for the primary reconstruction and revision-reconstruction cohorts.

## SUBJECT ELIGIBILITY

### *Subject Inclusion Criteria*

**Female**

1. Age limitation specific to the indication:
   - Primary Augmentation – Must be 18 years or older
   - Primary Reconstruction – No age limit
   - Revision – If original surgery was primary reconstruction, then no age limit. If original surgery was primary augmentation, then must be 18 years or older;
2. Adequate tissue available to cover the implant(s).
3. Willingness to follow study requirements (informed consent form, follow-up visits), and
4. Candidate for primary augmentation, primary reconstruction, or revision as defined below:

<u>Reconstruction –</u>

- Post-mastectomy or lumpectomy surgical removal of breast as result of cancer or other diseases
- Post trauma as defined as total or partial removal of breast(s) resulting in significant deformity (for any reason)
- Congenital deformities or acquired discrepancy in breast size such as to represent a significant physical deformity, which includes, but is not limited to pectus excavatum, pectus carinatum, scoliosis, Poland's Syndrome, and tuberous breast
- Contralateral augmentation mammoplasty as a result of the affected breast requiring surgery when medically indicated to provide symmetry

Augmentation –

- Severe ptosis
- General breast enlargement
- Asymmetry

Revision – replacement of an existing breast implant where medical or surgical reasons exist

***Subject Exclusion Criteria***

1. Advanced fibrocystic disease considered to be pre-malignant without mastectomy
2. Inadequate or unsuitable tissue (for example, due to radiation damage, ulceration, compromised vascularity, history of compromised wound healing)
3. Active infection in your body at the time of surgery
4. Pregnant or lactating
5. Medical condition in the judgment of the investigator such as obesity, diabetes, autoimmune disease, chronic lung or severe cardiovascular disease, that might result in unduly high surgical risk and/or significant post-operative complications
6. Use of drugs, including any drug that would interfere with blood clotting, that might result in high risk and/or significant post-operative complications
7. Demonstrates psychological characteristics, which are unrealistic or unreasonable with the risks involved with the surgical procedure;
8. It has been determined by physical examination that the subject may have a connective tissue/autoimmune disorders such as systemic lupus erythematosus, discoid lupus, or scleroderma;
9. Existing carcinoma of the breast without accompanying mastectomy
10. MRI scan is prohibited because of implanted metal device, claustrophobia or other conditions.

There were 1,788 patients who participated in the Clinical Study. A total of 1,116 patients had primary augmentation, 363 patients had revision-augmentation, 225 patients had primary reconstruction (152 CORE and 73 CA) and 84 patients (52 CORE and 32 CA) had revision reconstruction with Sientra Implants. Of these patients, 398 primary augmentation patients, 115 revision-augmentation patients, 48 primary reconstruction patients, and 10 revision-reconstruction patients were assessed for implant rupture by MRI at years 3, 4, 6, 8, and 10 years. A total of 37 investigators (including transfer follow-up investigators) followed patients in the four cohorts.



Study patients were expected to complete follow-up visits for safety and effectiveness at 6 weeks post-surgery, then annually through 10 years Study patients were expected to complete follow-up visits for rheumatological questionnaires at year one, year two, and every other year after that post operation. Study patients were expected to complete follow-up visits for QOL questionnaires at year one, year two, and every other year after that post operation.

Assessment of the safety of the Study Implants was based on the incidence of all complications, including device failures, and adverse device effects, on a per-implant and per-patient basis. There were 63 patients (69 implants) that had rupture, which was 7.9% of the patients at ten years. Of those 63 patients, 36 patients had silent rupture identified in the MRI cohort. The remaining 27 patients with ruptures were identified in the non-MRI cohort; one rupture being identified via mammogram, (2.8%), and other ruptures (16.7%) were identified at explantation. Originally, 32% of study subjects participated in an MRI cohort to receive MRIs at regular intervals. Upon FDA device approval in 2012, all subjects were expected to obtain MRIs at regular intervals. MRI compliance at the 10-year time point was 56.5%. Other potential complications of the breast implant surgery assessed by the Study include possible systemic effects (e.g., autoimmune and/or rheumatologic effects).

Assessment of effectiveness was based on changes in bra size/chest circumference taken at Years 1 and 2, and patient-reported quality-of-life (QOL) outcomes, including the Short Form Health Survey (SF-36), the Rosenberg Self-Esteem Scale, and the Body Image Scale assessed through 10 years.

The final, 10-year results of the Study demonstrate that the Implants continue to be safe and effective for use in primary augmentation, revision-augmentation, primary reconstruction, and revision-reconstruction of the breast. The final 10-year safety assessment of the Implants reveals clinically acceptable rates for complications. Additionally, the effectiveness outcomes demonstrate that the majority of subjects continue to report favorable satisfaction and QOL results. Clinical results include data collected through the database closing date of November 15, 2017.

## STUDY STRENGTHS AND WEAKNESSES

Study strengths include the fact that the Study is a multicenter, prospective long-term (10-year) study with a large sample size and adequate statistical power to estimate important health-related endpoints. Further strengths include the datum that safety outcomes were assessed and collected by surgeons during physical examination of their patients at follow-up office visits. Another potential strength is the enrollment of a mix of Sientra's various Implant styles, which provides results for a variety of styles.

Study weaknesses include the Study enrollment was not separated to enroll Implant styles equally across the Study (and not equally within each cohort). This may be a weakness because particular styles were enrolled at higher rates and may be associated with varying outcomes.

An additional Study weakness includes follow up compliance rates for the four cohorts ranging from 58% to 67%. The MRI compliance rates include 69.9% for the MRI cohort and 48.9% for the non- MRI cohort, and an overall MRI compliance for both the MRI and non-MRI cohorts of 56.5%. In addition, this study was not designed to detect rare events that may occur in women undergoing breast implantation surgery nor do the complications represent all possible postoperative complications for those undergoing breast implant surgery. Results may not be generalizable to a larger population. Additional study weaknesses may include the lack of a control group.

## PATIENT ACCOUNTING AND DEMOGRAPHICS

There were 1,788 patients who participated in the Clinical Study. A total of 1,116 patients had primary augmentation, 363 patients had revision-augmentation, 225 patients had primary reconstruction (152 CORE and 73 CA) and 84 patients (52 CORE and 32 CA) had revision reconstruction with Sientra Implants. Of these patients, 398 primary augmentation patients, 115 revision-augmentation patients, 48 primary reconstruction patients, and 10 revision-reconstruction patients are assessed for implant rupture by MRI at years 3, 4, 6, 8, and 10 years. A total of 37 investigators (including transfer follow-up investigators) followed patients in the four cohorts.

Study patients were expected to complete follow-up visits for safety and effectiveness at 6 weeks post-surgery, then annually through 10 years. Study patients were expected to complete follow-up visits for rheumatological questionnaires at year one, year two, and every other year after that post operation. Study patients were expected to complete follow-up visits for QOL questionnaires at year one, year two, and every other year after that post operation. .

Final 10-year Clinical Study data available for 67% of the eligible primary augmentation patients, 62% of the eligible revision-augmentation patients, 65% of the eligible primary reconstruction patients, and 58% of the revision reconstruction patients, for an overall final Study follow-up compliance of 65%. Table 2 provides a tabulation of the 10-year patient accounting.

**Table 2. Patient Accounting**

| Follow-up Year | Study Cohort | | | |
|---|---|---|---|---|
| | Primary Augmentation | Revision Augmentation | Primary Reconstruction | Revision Reconstruction |
| **Year 1** | | | | |
| Theoretically Due | 1,116 | 363 | 225 | 84 |
| Discontinued (Deaths & Explants) | 4 (0 & 4) | 7 (1 & 6) | 12 (1 & 11) | 6 (0 & 6) |
| Expected | 1,107 | 355 | 208 | 77 |
| Other Discontinued (Not Available & Subject Request) | 5 (3 & 2) | 1 (0 & 1) | 5 (0 & 5) | 1 (0 & 1) |
| Lost to Follow-up | 9 | 8 | 17 | 7 |
| Actual Evaluated (% Follow-up) | 1,018 (92%) | 317 (89%) | 192 (92%) | 68 (88%) |
| **Year 2** | | | | |
| Theoretically Due | 1,116 | 363 | 225 | 84 |
| Discontinued (Deaths & Explants) | 14 (0 & 14) | 15 (2 & 13) | 14 (1 & 13) | 12 (1 & 11) |
| Expected | 1093 | 345 | 205 | 71 |
| Other Discontinued (Not Available & Subject Request) | 9 (3 & 6) | 3 (1 & 2) | 6 (0 & 6) | 1 (0 & 1) |
| Lost to Follow-up | 23 | 18 | 20 | 13 |
| Actual Evaluated (% Follow-up) | 928 (85%) | 296 (86%) | 176 (86%) | 62 (87%) |
| **Year 3** | | | | |
| Theoretically Due | 1,116 | 363 | 225 | 84 |
| Discontinued (Deaths & Explants) | 23 (0 & 23) | 21 (2 & 19) | 16 (3 & 13) | 14 (2 & 12) |
| Expected | 1,081 | 338 | 203 | 67 |
| Other Discontinued (Not Available & Subject Request) | 12 (3&9) | 4 (1 & 3) | 6 (0 & 6) | 3 (0 & 3) |

## Table 2. Patient Accounting

| Follow-up Year | Study Cohort | | | |
|---|---|---|---|---|
| | Primary Augmentation | Revision Augmentation | Primary Reconstruction | Revision Reconstruction |
| Lost to Follow-up | 35 | 25 | 22 | 17 |
| Actual Evaluated (% Follow-up) | 885 (82%) | 274 (81%) | 170 (84%) | 53 (79%) |
| **Year 4** | | | | |
| Theoretically Due | 1,116 | 363 | 225 | 84 |
| Discontinued (Deaths & Explants) | 31 (1 & 30) | 26 (3 & 23) | 21 (4 & 17) | 14 (2 & 12) |
| Expected | 1,066 | 333 | 197 | 67 |
| Other Discontinued (Not Available & Subject Request) | 19 (3 & 16) | 4 (1 & 3) | 7 (0 & 7) | 3 (0 & 3) |
| Lost to Follow-up | 50 | 30 | 28 | 17 |
| Actual Evaluated (% Follow-up) | 865 (81%) | 268 (81%) | 159 (81%) | 53 (79%) |
| **Year 5** | | | | |
| Theoretically Due | 1,116 | 363 | 225 | 84 |
| Discontinued (Deaths & Explants) | 40 (4 & 36) | 35 (4 & 31) | 23 (4 & 19) | 16 (2 & 14) |
| Expected | 1,049 | 324 | 194 | 65 |
| Other Discontinued (Not Available & Subject Request) | 27 (4 & 23) | 4 (1 & 3) | 8 (0 & 8) | 3 (0 & 3) |
| Lost to Follow-up | 67 | 39 | 31 | 19 |
| Actual Evaluated (% Follow-up) | 837 (80%) | 250 (77%) | 148 (76%) | 52 (80%) |
| **Year 6** | | | | |
| Theoretically Due | 1,116 | 363 | 225 | 84 |
| Discontinued (Deaths & Explants) | 52 (5 & 47) | 37 (4 & 33) | 28 (7 & 21) | 18 (2 & 16) |
| Expected | 1,032 | 321 | 188 | 62 |
| Other Discontinued (Not Available & Subject Request) | 32 (6 & 26) | 5 (1 & 4) | 9 (0 & 9) | 4 (0 & 4) |
| Lost to Follow-up | 84 | 42 | 37 | 22 |
| Actual Evaluated (% Follow-up) | 781 (76%) | 238 (74%) | 145 (77%) | 48 (77%) |
| **Year 7** | | | | |
| Theoretically Due | 1,116 | 363 | 225 | 84 |
| Discontinued (Deaths & Explants) | 59 (6 & 53) | 40 (4 & 36) | 31 (9 & 22) | 19 (2 & 17) |
| Expected | 1,021 | 316 | 182 | 59 |



## Table 2. Patient Accounting

| Follow-up Year | Study Cohort | | | |
|---|---|---|---|---|
| | Primary Augmentation | Revision Augmentation | Primary Reconstruction | Revision Reconstruction |
| Other Discontinued (Not Available & Subject Request) | 36 (6 & 30) | 7 (1 & 6) | 12 (1 & 11) | 6 (0 & 6) |
| Lost to Follow-up | 95 | 47 | 43 | 25 |
| Actual Evaluated (% Follow-up) | 723 (71%) | 218 (69%) | 129 (71%) | 43 (73%) |
| **Year 8** | | | | |
| Theoretically Due | 1,116 | 363 | 225 | 84 |
| Discontinued (Deaths & Explants) | 65 (7 & 58) | 44 (4 & 40) | 36 (10 & 26) | 23 (4 & 19) |
| Expected | 1,008 | 305 | 175 | 52 |
| Other Discontinued (Not Available & Subject Request) | 43 (7 & 36) | 14 (1 & 13) | 14 (3 & 11) | 9 (1 & 8) |
| Lost to Follow-up | 108 | 58 | 50 | 32 |
| Actual Evaluated (% Follow-up) | 635 (63%) | 182 (60%) | 116 (66%) | 37 (71%) |
| **Year 9** | | | | |
| Theoretically Due | 1,116 | 363 | 225 | 84 |
| Discontinued (Deaths & Explants) | 77 (8 & 69) | 47 (4 & 43) | 41 (14 & 27) | 26 (6 & 20) |
| Expected | 995 | 301 | 170 | 48 |
| Other Discontinued (Not Available & Subject Request) | 44 (7 & 37) | 15 (1 & 14) | 14 (3 & 11) | 10 (1 & 9) |
| Lost to Follow-up | 121 | 62 | 55 | 36 |
| Actual Evaluated (% Follow-up) | 685 (69%) | 205 (68%) | 123 (72%) | 32 (67%) |
| **Year 10** | | | | |
| Theoretically Due | 1,116 | 363 | 225 | 84 |
| Discontinued (Deaths & Explants) | 88 (10 & 78) | 51 (4 & 47) | 43 (15 & 28) | 29 (8 & 21) |
| Expected | 978 | 294 | 166 | 43 |
| Other Discontinued (Not Available & Subject Request) | 50 (9 & 41) | 18 (1 & 17) | 16 (3 & 13) | 12 (1 & 11) |
| Lost to Follow-up | 138 | 69 | 59 | 41 |
| Actual Evaluated (% Follow-up) | 688 (70%) | 192 (65%) | 118 (71%) | 32 (74%) |

Demographic information for the Study with regard to race is as follows: 92% of the Study patients were Caucasian; 3% were Hispanic; 2% were Asian, 2% were African American; less than 1% were Indian and less than 2% were other or unknown. The median age at surgery was 36 years for primary augmentation patients, 42 years for revision-augmentation patients, 46 years for primary reconstruction patients, and 51 years for revision-reconstruction patients. Approximately 59% of the Study patients were married. Approximately 74% had some college education. Table 3 presents the Study population demographics at baseline by cohort.

**Table 3. Patient Demographics by Cohort**

| Characteristic | Primary Augmentation N=1,116 | Revision Augmentation N=363 | Primary Reconstruction N=225 | Revision Reconstruction N=84 |
|---|---|---|---|---|
| **Age (years)** | | | | |
| ≤ 21 | 47 (4.2%) | 3 (0.8%) | 9 (4.0%) | 0 (0%) |
| 22-25 | 102 (9.1%) | 12 (3.3%) | 5 (2.2%) | 0 (0%) |
| 26-39 | 566 (50.7%) | 128 (35.3%) | 55 (24.4%) | 8 (9.5%) |
| 40-49 | 335 (30.0%) | 139 (38.3%) | 67 (29.8%) | 26 (31.0%) |
| 50-59 | 57 (5.1%) | 63 (17.4%) | 62 (27.6%) | 29 (34.5%) |
| 60-69 | 8 (0.7%) | 18 (5.0%) | 17 (7.6%) | 14 (16.7%) |
| 70 & over | 1 (0.1%) | 0 (0%) | 10 (4.4%) | 7 (8.3%) |
| Median Age | 36 years | 42 years | 46 years | 51 years |
| **Marital Status** | | | | |
| Single | 317 (28.4%) | 92 (25.3%) | 47 (20.9%) | 14 (16.7%) |
| Married | 641 (57.4%) | 217 (59.8%) | 142 (63.1%) | 59 (70.2%) |
| Widowed | 9 (0.8%) | 9 (2.5%) | 6 (2.7%) | 5 (6.0%) |
| Divorced | 126 (11.3%) | 42 (11.6%) | 26 (11.6%) | 6 (7.1%) |
| Separated | 21 (1.9%) | 3 (0.8%) | 1 (0.4%) | 0 (0%) |
| Not Provided | 2 (0.2%) | 0 (0%) | 3 (1.3%) | 0 (0%) |
| **Race** | | | | |
| Caucasian | 1,014 (90.9%) | 338(93.1%) | 204 (90.7%) | 80 (95.2%) |
| Black | 12 (1.1%) | 7 (1.9%) | 5 (2.2%) | 2 (2.4%) |
| Hispanic | 37 (3.3%) | 7 (1.9%) | 10 (4.4%) | 1 (1.2%) |
| Asian | 29 (2.6%) | 8 (2.2%) | 1 (0.4%) | 0 (0%) |
| Indian | 1 (0.1%) | 0 (0%) | 1 (0.4%) | 0 (0%) |
| Other | 22 (2.0%) | 2 (0.6%) | 2 (0.9) | 1 (1.2%) |
| Not Provided | 1 (0.1%) | 1 (0.3%) | 2 (0.9%) | 0 (0%) |
| **Education** | | | | |



**Table 3. Patient Demographics by Cohort**

| Characteristic | Primary Augmentation N=1,116 | Revision Augmentation N=363 | Primary Reconstruction N=225 | Revision Reconstruction N=84 |
|---|---|---|---|---|
| Less than 12 years | 8 (0.7%) | 4 (1.1%) | 5 (2.2%) | 1 (1.2%) |
| High School Graduate | 187 (16.8%) | 68 (18.7%) | 71 (31.6%) | 24 (28.6%) |
| Some College | 368 (33.0%) | 95 (26.2%) | 52 (23.1%) | 24 (28.6%) |
| College Graduate | 399 (35.8%) | 150 (41.3%) | 61 (27.1%) | 22 (26.2%) |
| Post-Graduate | 94 (8.4%) | 26 (7.2%) | 18 (8.0%) | 6 (7.1%) |
| Not Provided | 60 (5.4% | 20 (5.5%) | 18 (8.0%) | 7 (8.3%) |

With respect to surgical approach, for primary augmentation patients, the majority of implants (62%) were placed through an inframammary incision; 34% of implants were placed through a periareolar incision, 3.9% were placed through a transaxillary incision and 0.9% included a mastopexy procedure. The placement was submuscular in 57% of implants and subglandular in 43% of implants. Round implants represented 89% of total implants and shaped implants represented 12% of total implants. Smooth implants represented 58% of implants and textured implants represented 42% of implants.

For revision-augmentation patients, the majority of implants (61%) were placed through an inframammary incision; 33% of implants were placed through a periareolar incision, 3.3% were placed through a transaxillary incision, 2.2% were placed through a mastopexy procedure and 0.3% were placed through a mastectomy or other scar incision. The placement was submuscular in 61% of implants and subglandular in 39% of implants. Round implants represented 86% of implants and shaped implants represented 14% of implants. Smooth implants represented 47% of implants and textured implants represented 53% of implants.

For primary reconstruction patients, the most commonly used surgical approach for implant placement (45%) was through a mastectomy or other scar, 29% were placed through an inframammary incision, and 16% of implants were placed through a periareolar incision, 6.6% were placed through a mastopexy procedure and 3.2% were placed through a transaxillary incision. The placement was submuscular in 73% of implants and subglandular in 27% of implants. Round implants represented 88% of implants and shaped implants represented 12% of implants. Smooth implants represented 46% of implants and textured implants represented 54% of implants.

For revision- reconstruction patients, the majority of implants (55%) were placed through a mastectomy or other scar, 33% were placed through an inframammary incision; 7% of implants were placed through a periareolar incision, and 2% were placed through a transaxillary incision and 0.7% were placed through a mastopexy procedure. The placement was submuscular in 90% of implants and subglandular in 9% of implants. Round implants represented 87% of implants and shaped implants represented 13% of implants. Smooth implants represented approximately 40.3% of implants and textured implants represented 59.7% of implants. See Tables 4 and 5 for full details of breast implants by placement and surgical approach, and breast implant style, respectively.

**Table 4. Breast Implant Placement & Surgical Approach by Cohort**

| Surgical Characteristic | Primary Augmentation N=2,230 | Revision Augmentation N=725 | Primary Reconstruction N=412 | Revision Reconstruction N=139 |
|---|---|---|---|---|
| **Implant Placement** | | | | |
| Submuscular | 1,273 (57.1%) | 440 (60.7%) | 300 (72.8%) | 125 (89.9%) |
| Subglandular | 957 (42.90%) | 285 (39.3%) | 112 (27.2%) | 14 (10.1%) |
| **Total** | 2,230 | 725 | 412 | 139 |
| **Surgical Approach** | | | | |
| Inframammary | 1,374 (61.6%) | 441 (60.8%) | 117 (28.4%) | 47 (33.8%) |
| Mastectomy scar | 0 (0%) | 2 (0.3%) | 187 (45.4%) | 79 (56.8%0 |
| Mastopexy | 20 (0.9%) | 16 (2.2%) | 27 (6.6%) | 1 (0.7%) |
| Periareolar | 748 (33.5%) | 242 (33.4%) | 68 (16.5%) | 9 (6.5%) |
| Transaxillary | 88 (3.9%) | 24 (3.3%) | 13 (3.2%) | 3 (2.2%) |
| **Total** | **2,230** | **725** | **412** | **139** |

**Table 5. Breast Implant Style by Cohort**

| Product Style/ Projection[1] | Primary Augmentation N=2,230 | Revision Augmentation N=725 | Primary Reconstruction N=412 | Revision Reconstruction N=139 |
|---|---|---|---|---|
| **Round Styles** | | | | |
| Style 10512 (Smooth)/MP | 716 (32.1%) | 136 (18.8%) | 79 (19.2%) | 20 (14.4%) |
| Style 10521 (Smooth)/HP | 572 (25.7%) | 204 (28.1%) | 110 (26.7%) | 36 (25.9%) |
| Style 20610 (Textured)/LP | 99 (4.4%) | 36 (5.0%) | 28 (6.8%) | 3 (2.2%) |
| Style 20621 (Textured)/MP/HP | 587 (26.3%) | 248 (34.2%) | 144 (35%) | 63 (45.3%) |
| **Shaped Styles** | | | | |
| Style 20645 (Textured)/LP | 54 (2.4%) | 12 (1.7%) | 10 (2.4%) | 11 (7.9%) |
| Style 20646 (Textured)/HP | 0 (0%) | 0 | 1 (0.2%) | 3 (2.2%) |
| Style 20676 (Textured)E/MP | 202 (9.1%) | 89 (12.3%) | 40 (9.7%) | 3 (2.2%) |

[1]Projections include LP=Low Profile, MP, or E=Moderate Profile, HP=High Profile

The final results of the 10-year Clinical Study are presented in this IFU. Information on the safety and benefits of Sientra Implants is presented below and organized by indication. In addition, updates regarding Sientra's Clinical study and post market safety information can be reviewed on Sientra's website at the "Commitment to Safety" webpage (https://sientra.com/commitment-to-safety/).

## RUPTURE INFORMATION ON SIENTRA'S IMPLANTS

Out of a total cohort of 3,506 implants in 1,788 patients, follow-up MRI compliance rates were 69.9% for the MRI cohort, 48.9% for the non-MRI cohort, with an MRI compliance rate at the 10-year time point of 56.5%. There have been 36 confirmed ruptures (35 confirmed silent rupture which were confirmed upon explant and 1 confirmed symptomatic rupture which was confirmed upon explant) though year 10. These ruptures and suspected ruptures include 24 confirmed and 21 unconfirmed implant ruptures occurring in 42 primary augmentation patients (bilateral ruptures were reported in 3 patients); six confirmed and five unconfirmed implant ruptures occurring in nine

revision-augmentation patients; four confirmed and four unconfirmed implant ruptures occurring in seven primary reconstruction patients; and two confirmed and 3 unconfirmed ruptures occurring in five revision-reconstruction patients. Based on analysis of the patients' data in the MRI cohort, the Kaplan-Meier calculated by-patient risk of rupture through 10-years is 8.6%. By cohort, the 10-year Kaplan-Meier risk of rupture was 8.5% for primary augmentation patients, 6.8% for revision-augmentation patients and 16.5% for primary reconstruction patients. There were no ruptures identified among the revision-reconstruction patients who underwent MRI through 10 years. Since the overall rate includes both the MRI and non-MRI cohorts, the rate of MRI rupture for the MRI cohort may be underestimated. Table 6 provides a summary of the Kaplan-Meier risk of rupture in the MRI cohort through 10 years, MRI data was collected at years 4, 6, 8 and 10.

- 39% of implants with suspected silent ruptures were confirmed to be intact upon explantation or follow-up MRI
- All but 1 of the 36 explanted ruptures were found to be intracapsular

**Table 6. KM Risk (95% CI) of Rupture Original (pre-PMA approval) MRI Cohort by Patient**

| Timepoint | KM Risk (95% CI) | | | |
|---|---|---|---|---|
| | Primary Augmentation N=398 | Revision Augmentation N=115 | Primary Reconstruction N=48 | Revision Reconstruction N=10 |
| Year 1 | -- | -- | -- | |
| Year 2 | -- | -- | -- | -- |
| Year 3 | -- | -- | -- | |
| Year 4 | 1.3% (0.5%, 3.1%) | -- | -- | -- |
| Year 5 | 2.4% (1.3%, 4.6%) | 0.9% (0.1%, 6.4%) | -- | -- |
| Year 6 | 4.2% (2.5%, 6.9%) | 2.9% (1.0%, 8.8%) | 2.8% (0.4%, 18.1%) | -- |
| Year 7 | 5.9% (3.8%, 9.0%) | 4.0% (1.5%, 10.4%) | 2.8% (0.4%, 18.1%) | -- |
| Year 8 | 6.3% (4.1%, 9.5%) | 4.0% (1.5%, 10.4%) | 2.8% (0.4%, 18.1%) | -- |
| Year 9 | 7.9% (5.4%, 11.6%) | 4.0% (1.5%, 10.4%) | 6.7% (1.7%, 24.6%) | -- |
| Year 10 | 8.5% (5.8%, 12.4%) | 6.8% (3.1%, 14.7%) | 16.5% (6.3%, 39.1%) | -- |

Tables 7 through 10 compare KM estimated cumulative incidence of rupture in all four cohorts, based on the last MRI exam through 10 years for both the MRI and non-MRI cohorts where rupture was either suspected or confirmed, or confirmed.

**Table 7. Suspected or Confirmed Kaplan-Meier Estimated Cumulative Incidence of Rupture Based on Last MRI Exam through 10 years – Augmentation Patients**

| MRI Cohort | | Non-MRI Cohort | |
|---|---|---|---|
| Enrolled: 398 patients with 795 implants<br>MRI Follow-up compliance at 10 years:<br>224/327 patients (68.5%) | | Enrolled: 718 patients with 1435 implants<br>MRI Follow-up compliance at 10 years:<br>261/529 patients (49.3%) | |
| ***Suspected or Confirmed***<br>26 patients<br>28 implants | **Kaplan-Meier estimated rate (95% Confidence Interval)**<br>8.5% (5.8%, 12.4%)<br>4.7% (3.2%, 6.7%) | ***Suspected or Confirmed***<br>16 patients<br>17 implants | **Kaplan-Meier estimated rate (95% Confidence Interval)**<br>6.3% (3.9%, 10.1%)<br>3.4% (2.1%, 5.4%) |

**Table 8. Suspected or Confirmed Kaplan-Meier Estimated Cumulative Incidence of Rupture Based on Last MRI Exam through 10 years – Revision Augmentation Patients**

| MRI Cohort | | Non-MRI Cohort | |
|---|---|---|---|
| Enrolled: 115 patients with 230 implants<br>MRI Follow-up compliance at 10 years:<br>71/94 patients (75.5%) | | Enrolled: 248 patients with 495 implants<br>MRI Follow-up compliance at 10 years<br>71/168 patients (42.3%) | |
| ***Suspected or Confirmed***<br>6 patients<br>7 implants | **Kaplan-Meier estimated rate (95% Confidence Interval)**<br>6.8% (3.1%, 14.7%)<br>4.0% (1.9%, 8.2%) | ***Suspected or Confirmed***<br>3 patients<br>4 implants | **Kaplan-Meier estimated rate (95% Confidence Interval)**<br>3.5% (1.1%, 10.4%)<br>2.4% (0.9%, 6.4%) |

**Table 9. Suspected or Confirmed Kaplan-Meier Estimated Cumulative Incidence of Rupture Based on Last MRI Exam through 10 years – Reconstruction Patients**

| MRI Cohort | | Non-MRI Cohort | |
|---|---|---|---|
| Enrolled: 48 patients with 91 implants<br>MRI Follow-up compliance at 10 years: 23/34 patients (67.6%) | | Enrolled: 177 patients with 321 implants<br>MRI Follow-up compliance at 10 years: 49/87 patients (56.3%) | |
| ***Suspected or Confirmed*** | **Kaplan-Meier estimated rate (95% Confidence Interval)** | ***Suspected or Confirmed*** | **Kaplan-Meier estimated rate (95% Confidence Interval)** |
| 4 patients<br>4 implants | 16.5% (6.3%, 39.1%)<br>8.9% (3.4%, 22.5%) | 3 patients<br>4 implants | 6.6% (2.1%, 19.3%)<br>4.9% (1.8%, 12.6%) |

**Table 10 Suspected or Confirmed Kaplan-Meier Estimated Cumulative Incidence of Rupture Based on Last MRI Exam through 10 years – Revision Reconstruction Patients**

| MRI Cohort | | Non-MRI Cohort | |
|---|---|---|---|
| Enrolled: 10 patients with 19 implants<br>MRI Follow-up compliance at 10 years: 3/4 patients (75.0%) | | Enrolled: 74 patients with 120 implants<br>MRI Follow-up compliance at 10 years: 14/24 implants (58.3%) | |
| ***Suspected or Confirmed*** | **Kaplan-Meier estimated rate (95% Confidence Interval)** | ***Suspected or Confirmed*** | **Kaplan-Meier estimated rate (95% Confidence Interval)** |
| 0 patients<br>0 implants | --<br>-- | 5 patients<br>5 implants | NR*<br>NR* |

*Some rates are not reported because number of remaining patients/implants is <10.

In addition to the rupture data described in Sientra's prospective Clinical study, Sientra also collected information via a separate prevalence study. In this study MRI examinations were performed on 274 Implants in 140 women that assessed the rate of asymptomatic (or "silent") rupture in patients who received Silicone-Gel Breast Implants between 1990 and 2000. Overall, the long-term prevalence of rupture in the study was 7.7% by implant and 12.1% by patient, with a median implantation age of 14.4 years. In comparison, those implants with no evidence of rupture via MRI have a median duration of 10.2 years.



While recognizing that not all implants in the study were identical to the implants currently manufactured by Sientra, these data support the low rate of rupture found in Sientra's Clinical Study and suggests that even over the long-term, over 14 years, Sientra's Silicone Gel Breast Implants have a relatively low rate of rupture. Additional information on rupture will be collected through Sientra's ongoing post approval study.

## PRIMARY AUGMENTATION AND REVISION-AUGMENTATION PATIENTS

The benefits and complications reported in the Study for primary and revision-augmentation patients are described below.

## PATIENT ACCOUNTING AND FOLLOW-UP RATES

The Study enrolled 1,116 primary augmentation patients. Of the women expected to be seen at the 10-year follow-up visit, 67% were seen.

The Study enrolled 363 revision-augmentation patients. Of the women expected to be seen at the 10-year follow-up visit, 62% were seen.

## EFFECTIVENESS OUTCOMES

The benefits of Sientra Silicone Gel Breast Implants were determined by measuring bra size/chest circumference change and assessing patient satisfaction using patient-reported quality-of-life (QOL) outcomes, including the Short Form Health Survey (SF-36), the Rosenberg Self-Esteem Scale, and the Body Image Scale. The information was collected before implantation and at scheduled follow-up visits.

### Primary Augmentation Patients

For primary augmentation patients, 91% of patients increased their bra cup size by at least one cup size. Eighty-two percent (82%) of patients increased their bra cup size by one to two cups, while 10% gained more than two cup sizes. The change in bra cup size is unknown for the remaining 3% of patients.

The majority of primary augmentation patients were satisfied with their results. Other findings of the Study showed that most patients agreed their breast implants make them feel more feminine (89%) and more attractive (86%). In addition, the majority of women indicated that their breast implants made them feel better about themselves (77%).

For primary augmentation patients, comparisons of Baseline QOL scores to scores at Year 10 showed statistically significant decreases in some of the quality-of-life scales (decreases ranged between -3.7 to -8.9 within the 0-100-point scales, and effect sizes ranged between 0.33-0.60). Statistical significance was defined as those with an Effect Size >0.20 and p-value <0.05 (using a GEE model).

For primary augmentation patients, mean total self-esteem scores on the Rosenberg Self-Esteem Scale at Baseline and Year 10 remained above 25. Scores between 15 and 25 are considered to be within normal range, with higher scores indicating more positive feelings.

Mean scores on the Body Esteem Scale and subscales also remain high from Baseline to Year 10 among women in the primary augmentation cohort. One sub-scale (Sexual attractiveness) had no change while the remaining subscales (Physical Condition and Weight concern subscales) as well as the Overall Body Esteem Scale show statistically significant changes from baseline to Year 10, where the magnitude of the negative change was slight, ranging between -0.2 and -0.3.

### Revision-Augmentation Patients

Bra cup size was not measured in revision-augmentation patients.

Through 10-years of the Clinical Study the majority of revision-augmentation patients continued to be satisfied with their results. Another finding of the Study showed that most patients agreed that their breast implants make them feel more feminine (87%) and more attractive (83%). In addition, the majority of women indicated that their breast implants made them feel better about themselves (78%).

For revision-augmentation patients, comparison of baseline QOL scores to scores at Year 10 showed a number of statistically significant decreases in some of the quality-of-life scales (decreases ranged between -4.8 to -8.7 within the 0-100-point scales, and effect sizes ranged between 0.34-0.68). Statistical significance was defined as those with an Effect Size >0.20 and p-value <0.05 (using a GEE model).

For revision-augmentation patients, mean total scores on the Rosenberg Self-Esteem Scale at Baseline and Year 10 remained above 25, with no statistically significant difference. Scores between 15 and 25 are considered to be within normal range, with higher scores indicating more positive feelings.



Mean scores on the Body Esteem Scale and subscales also remain high from Baseline to Year 10 among women in the revision-augmentation cohort. The Physical Condition and Weight concern subscales, as well as the Overall Body Esteem Scale show statistically significant decreases from baseline to Year 10, where the magnitude of change ranged between -0.2 and -0.3.

## SAFETY OUTCOMES

The safety of Sientra Implants was determined by assessing the incidence of complications, including device failures.

### Primary Augmentation Patients

Table 11 describes the Kaplan-Meier risk of complications experienced for the primary augmentation patients in the Study at 3, 6, and 10-years.

**Table 11. Kaplan-Meier Risk of Complications for Primary Augmentation Patients (N=1,116 Patients)**

| Key Complications | 3-yr KM Risk (95% CI) | 6-yr KM Risk (95% CI) | 10-yr KM Risk (95% CI) |
|---|---|---|---|
| Reoperation | 12.8% (10.9%, 15.0%) | 17.9% (15.7%, 20.5%) | 24% (21.4%, 26.8%) |
| Capsular Contracture (Baker Grade III/IV) | 5.9% (4.7%, 7.6%) | 9.7% (8.1%, 11.9%) | 12.9% (10.8%, 15.2%) |
| Implant Removal with Replacement | 4.4% (3.3%, 5.9%) | 7.9% (6.4%, 9.7%) | 12.2% (10.3%, 14.5%) |
| Implant Rupture (MRI cohort)[1] | 0 | 4.2% (2.5%, 6.9%) | 8.5% (5.8%, 12.4%) |
| Implant Removal without Replacement | 1.3% (0.8%, 2.3%) | 2.7% (1.8%, 3.9%) | 4.7% (3.5%, 6.4%) |
| **Other Complications Occurring at a KM Risk ≥1%[2,3]** | | | |
| Nipple Sensation Changes | 2.1% (1.4%, 3.2%) | 4.0% (2.9%, 5.4%) | 5.9% (4.5%, 7.7%) |
| Ptosis | 1.6% (1.0%, 2.6%) | 2.8% (2.0%, 4.1%) | 4.6% (3.4%, 6.2%) |
| Breast Mass/Cyst/Lump | 0.5% (0.2%, 1.2%) | 2.2% (1.4%, 4.3%) | 3.5% (2.5%, 5.0%) |
| Implant Malposition | 1.4% (0.9%, 2.3%) | 2.1% (1.4%, 3.2%) | 2.7% (1.8%, 4.0%) |
| Asymmetry | 1.0% (0.6%, 1.9%) | 1.2% (0.7%, 2.1%) | 2.0% (1.3%, 3.2%) |
| Wrinkling/Rippling | 0.8% (0.4%, 1.5%) | 1.2% (0.7%, 2.1%) | 1.9% (1.2%, 3.1%) |
| Breast Pain | 0.8% (0.4%, 1.6%) | 0.8% (0.4%, 1.6%) | 1.2% (0.7%, 2.2%) |
| Seroma/Fluid Accumulation | 0.7% (0.3%, 1.4%) | 0.8% (0.4%, 1.5%) | 1.2% (0.6%, 2.1%) |
| Hypertrophic/Abnormal Scarring | 0.7% (0.3%, 1.4%) | 0.9% (0.5%, 1.7%) | 1.0% (0.5%, 1.9%) |

**Table 11. Kaplan-Meier Risk of Complications for Primary Augmentation Patients (N=1,116 Patients)**

| Key Complications | 3-yr KM Risk (95% CI) | 6-yr KM Risk (95% CI) | 10-yr KM Risk (95% CI) |
|---|---|---|---|
| **Composite Category** | | | |
| Any Complication | 20.2% (17.9%, 22.9%) | 30.8% (28%, 33.9%) | 39.7% (36.7%, 42.9%) |

1. At 10 years, implant rupture was reported at a risk rate of 0%, 1.7% (0.8%, 3.3%) and 6.3% (3.9%, 10.1%) for the 3-year, 6-year, and 10-year timepoints, respectively in the non-MRI cohort.
2. The following complications were reported at a risk rate of less than 1%: bruising, delayed wound healing, hematoma, implant extrusion, implant palpability, implant visibility, infection, redness, skin sensation changes, swelling, upper pole fullness, and other complications.
3. None of the following complications were reported capsule calcification, irritation, lymphadenopathy, lymphedema, necrosis, nipple complications (not related to sensation), pneumothorax, and skin rash.

### Revision-Augmentation Patients

Table 12 describes the Kaplan-Meier risk of complications for the revision-augmentation patients in the Study at 3, 6, and 10-years.

**Table 12. Kaplan-Meier Risk of Complications for Revision-Augmentation Patients (N=363 Patients)**

| Key Complications | 3-yr KM Risk (95% CI) | 6-yr KM Risk (95% CI) | 10-yr KM Risk (95% CI) |
|---|---|---|---|
| Reoperation | 20.9% (16.9%, 25.6%) | 30.6% (25.9%, 35.9%) | 38.8% (33.6%, 44.6%) |
| Implant Removal with Replacement | 8.6% (6.1%, 12.1%) | 12.2% (9.1%, 16.3%) | 18.7% (14.7%, 23.7%) |
| Capsular Contracture (Baker Grade III/IV) | 6.2% (4.0%, 9.4%) | 11.5% (8.3%, 15.7%) | 13.7% (10.2%, 18.4%) |
| Implant Removal without Replacement | 2.7% (1.4%, 5.2%) | 5.6% (3.5%, 8.8%) | 9.4% (6.4%, 13.7%) |
| Implant Rupture (MRI cohort)[1] | 0% | 2.9% (1.0%, 8.8%) | 6.8% (3.1%, 14.7%) |
| **Other Complications Occurring at a KM Risk ≥1%[2,3]** | | | |
| Implant Malposition | 3.3% (1.9%, 5.8%) | 4.8% (2.9%, 7.9%) | 4.8% (2.9%, 7.9%) |
| Wrinkling/Rippling | 3.0% (1.6%, 5.5%) | 4.0% (2.3%, 6.8%) | 4.8% (2.9%, 7.9%) |
| Nipple Sensation Changes | 1.8% (0.8%, 4.0%) | 2.9% (1.5%, 5.5%) | 4.7% (2.7%, 8.0%) |
| Breast Mass/Cyst/Lump | 0% | 2.3% (1.1%, 5.1%) | 3.7% (1.9%, 7.0%) |
| Ptosis | 1.2% (0.5%, 3.2%) | 3.4% (1.8%, 6.2%) | 3.4% (1.8%, 6.2%) |
| Asymmetry | 2.0% (1.0%, 4.2%) | 2.7% (1.4%, 5.2%) | 2.7% (1.4%, 5.2%) |
| Breast Pain | 1.2% (0.5%, 3.2%) | 1.5% (0.6%, 3.7%) | 2.5% (1.2%, 5.2%) |
| Hypertrophic/Abnormal Scarring | 1.2% (0.5%, 3.2%) | 1.6% (0.7%, 3.8%) | 1.6% (0.7%, 3.8%) |
| Seroma/Fluid Accumulation | 1.2% (0.4%, 3.1%) | 1.6% (0.7%, 3.7%) | 1.6% (0.7%, 3.7%) |
| Infection | 1.2% (0.4%, 3.0%) | 1.5% (0.6%, 3.6%) | 1.5% (0.6%, 3.6%) |
| Skin Sensation Changes | 0.6% (0.2%, 2.4%) | 1.0% (0.3%, 3.0%) | 1.0% (0.3%, 3.0%) |
| **Any Complication** | | | |
| | 26.3% (21.8%, 31.4%) | 46.5% (40.9%, 52.4%) | 50.5% (45.1%, 56.2%) |

1. At 10-years, implant rupture was reported at a risk rate of 0.4% (0.1%, 2.9%), 0.9% (0.1%, 6.5%) and 3.5% (1.1%, 10.4%) for the 3-year, 6 year and 10-year timepoints, respectively in the non-MRI cohort.
2. The following complications were reported at a risk rate of less than 1%: bruising, delayed wound healing, hematoma, implant extrusion, implant palpability, implant visibility, irritation, necrosis, redness, swelling, upper pole fullness, and other complications.
3. None of the following complications were reported: capsule calcification, lymphadenopathy, lymphedema, nipple complications (not related to sensation), pneumothorax, and skin rash.

## REASONS FOR REOPERATION

### Primary Augmentation Patients

There were 291 reoperations performed in 236 primary augmentation patients through 10 years following implantation. Table 13 provides the primary reasons for reoperation in the augmentation cohort at 3, 6, and 10 years. The most common reasons for reoperation through 10 years in these patients were capsular contracture (25%) and patient request for change in the style or size of the implant (21%).

**Table 13. Main Reasons for Reoperation At Timepoints Through 10 Years For Primary Augmentation Patients**

| Main Reasons* for Reoperation | Through 3 Years Reoperations=149 Patients=127 n (%) | Through 6 Years Reoperations =229 Patients = 187 n (%) | Through 10 Years Reoperations=291 Patients = 236 n (%) |
|---|---|---|---|
| Suspected Rupture | 0 (0%) | 12 (5.2%) | 19 (6.5%) |
| Infection | 6 (4.0%) | 7 (3.1%) | 7 (2.4%) |
| Capsular Contracture | 33 (22.1%) | 58 (25.3%) | 72 (24.7%) |
| Healing Related | | | |
| Extrusion | 0 (0%) | 1 (0.4%) | 1 (0.3%) |
| Necrosis | 0 (0%) | 0 (0%) | 0 (0%) |
| Hematoma/Seroma | 17 (11.4%) | 21 (9.2%) | 23 (7.9%) |
| Delayed Wound Healing | 3 (2.0%) | 3 (1.3%) | 3 (1%) |
| Irritation/Inflammation | 0 (0%) | 0 (0%) | 0 (0%) |
| Pain | 1 (0.7%) | 1 (0.4%) | 1 (0.3%) |
| Cosmetic | | | |
| Malposition | 17 (11.4%) | 20 (8.7%) | 20 (6.9%) |
| Upper Pole Fullness | 1 (0.7%) | 1 (0.4%) | 1 (0.3%) |
| Wrinkling/Rippling | 4 (2.7%) | 4 (1.7%) | 6 (2.1%) |
| Palpability/Visibility | 0 (0%) | 0 (0%) | 1 (0.3%) |
| Asymmetry | 5 (3.4%) | 8 (3.5%) | 10 (3.4%) |
| Ptosis | 18 (12.1%) | 23 (10%) | 31 (10.7%) |
| Scarring/Hypertrophic Scarring | 8 (5.4%) | 10 (4.4%) | 10 (3.4%) |
| Nipple Related | 2 (1.3%) | 3 (1.3%) | 3 (1.0%) |
| Breast Cancer | 1 (0.7%) | 3 (1.3%) | 5 (1.7%) |
| Mass/Lump/Cyst | 2 (1.3%) | 8 (3.5%) | 9 (3.1%) |
| Skin Related | 0 (0%) | 0 (0%) | 0 (0%) |
| Style/Size Change | 29 (19.5%) | 43 (18.8%) | 60 (20.6%) |
| Trauma | 0 (0%) | 0 (0%) | 0 (0%) |
| Unknown | 2 (1.3%) | 3 (1.3%) | 9 (3.1%) |

*Some reoperations were performed for multiple reasons; only the primary reason is provided in the table.

## Revision-Augmentation Patients

There were 172 reoperations performed in 123 revision-augmentation patients through 10 years following implantation. Table 14 provides the main reasons for reoperation at 3, 6, and 10 years. In this population, the most common reasons for reoperation through 10 years were patient's desire for a change in the style or size of their implants (17%) and capsular contracture (16%).



**Table 14. Main Reasons for Reoperation At Timepoints Through 10 Years For Revision Augmentation Patients**

| Main Reasons* for Reoperation | Through 3 Years Reoperations = 84 Patients = 67 n (%) | Through 6 Years Reoperations = 139 Patients = 102 n (%) | Through 10 Years Reoperations = 172 Patients = 123 n (%) |
|---|---|---|---|
| Suspected Rupture | 0 (0%) | 1 (0.7%) | 4 (2.3%) |
| Infection | 3 (3.6%) | 4 (2.9%) | 4 (2.3%) |
| Capsular Contracture | 13 (15.5%) | 20 (14.4%) | 28 (16.3%) |
| Healing Related | | | |
| Extrusion | 1 (1.2%) | 1 (0.7%) | 1 (0.6%) |
| Necrosis | 0 (0%) | 1 (0.7%) | 1 (0.6%) |
| Hematoma/Seroma | 4 (4.8%) | 5 (3.6%) | 5 (2.9%) |
| Delayed Wound Healing | 5 (6.0%) | 5 (3.6%) | 5 (2.9%) |
| Irritation/Inflammation | 0 (0%) | 0 (0%) | 0 (0%) |
| Pain | 2 (2.4%) | 7 (5%) | 11 (6.4%) |
| Cosmetic | | | |
| Malposition | 11 (13.1%) | 14 (10%) | 14 (8.1%) |
| Upper Pole Fullness | 0 (0%) | 0 (0%) | 0 (0%) |
| Wrinkling/Rippling | 8 (9.5%) | 11 (7.9%) | 12 (7%) |
| Palpability/Visibility | 1 (1.2%) | 1 (0.7%) | 1 (0.6%) |
| Asymmetry | 5 (6.0%) | 10 (7.2%) | 11 (6.4%) |
| Ptosis | 5 (6.0%) | 13 (9.4%) | 13 (7.6%) |
| Scarring/Hypertrophic Scarring | 3 (3.6%) | 10 (7.2%) | 11 (6.4%) |
| Nipple Related | 1 (1.2%) | 1 (0.7%) | 1 (0.6%) |
| Breast Cancer | 1 (1.2%) | 2 (1.4%) | 4 (2.3%) |
| Mass/Lump/Cyst | 0 (0%) | 5 (3.6%) | 7 (4.1%) |
| Skin Related | 0 (0%) | 0 (0%) | 0 (0%) |
| Style/Size Change | 13 (15.5%) | 22 (15.8%) | 30 (17.4%) |
| Trauma | 0 (0%) | 0 (0%) | 0 (0%) |
| Other** | 1 (1.2%) | 1 (0.7%) | 1 (0.6%) |
| Unknown | 7 (8.3%) | 5 (3.6%) | 8 (4.7%) |

*Some reoperations were performed for multiple reasons; only the primary reason is provided in the table.
**Patient reported back pain from the weight of the Implants.

## REASONS FOR IMPLANT REMOVAL

### Primary Augmentation Patients

The main reasons for implant removal among primary augmentation patients through 10 years are provided in Table 15. There were 283 implants removed from 151 patients. Of these 283 implants, 74% were replaced. The most common reason for implant removal was the patient requesting a different implant style or size (49%).

**Table 15. Main Reason for Implant Removal through 10 Years for Primary Augmentation Patients (N=283 Implant Removals)**

| Reason for Removal | n (%) |
|---|---|
| Patient Request for Size/Style Change | 139 (49.1%) |
| Capsular Contracture | 53 (18.7%) |
| Suspected Rupture | 21 (7.4%) |
| Unknown | 17 (6.0%) |
| Ptosis | 14 (4.9%) |
| Infection | 8 (2.8%) |
| Wrinkling/Rippling | 8(2.8%) |
| Asymmetry | 7 (2.5%) |
| Hematoma/Seroma | 5 (1.8%) |
| Implant Malposition | 5 (1.8%) |
| Breast Cancer | 4 (1.4%) |
| Delayed Wound Healing | 1 (0.4%) |
| Implant Extrusion | 1 (0.4%) |

## Revision-Augmentation Patients

The main reasons for implant removal among revision-augmentation patients through 10 years are provided in Table 16. There were 144 implants removed from 79 patients. Of these 144 implants, most were replaced (69%). The most common reason for implant removal was the patient requesting a different implant style or size (44%).

**Table 16. Main Reason for Implant Removal through 10 Years for Revision-Augmentation Patients (N=144 Implant Removals)**

| Reason for Removal | n (%) |
|---|---|
| Patient Request for Size/Style Change | 63 (43.8%) |
| Capsular Contracture | 16 (11.1%) |
| Unknown | 15 (10.4%) |
| Wrinkling/Rippling | 11 (7.6%) |
| Asymmetry | 7 (4.9%) |
| Implant Malposition | 6 (4.2%) |
| Breast Cancer | 5 (3.5%) |
| Suspected Rupture | 5 (3.5%) |
| Infection | 4 (2.8%) |
| Ptosis | 4 (2.8%) |
| Hematoma/Seroma | 3 (2.1%) |
| Other | 2 (1.4%) |
| Scarring/Hypertrophic Scarring | 2 (1.4%) |
| Pain | 1 (0.7%) |



# OTHER CLINICAL FINDINGS

The Study evaluated several long-term health effects that have been reported in breast implant patients. These include cancer, connective tissue disease (CTD), CTD signs and symptoms, lactation complications, reproduction complications, and suicide. These endpoints, along with others, are being further evaluated as part of the Study and a Sientra post approval study of patients followed through 10 years

### Cancer

For primary augmentation patients, through 10 years, there have been five cases of breast cancer identified (0.6%). Diagnoses of any other (non-breast) cancers have been reported in 12 patients (1.1%) in the augmentation cohort through 10 years. There were four cases of fibrocystic breast disease (0.5%) in the primary augmentation cohort through 10 years.

For revision-augmentation patients, through 10 years, there have been four case of breast cancer (1.6%). Diagnoses of any other (non-breast) cancers have been reported in 4 patients (1.1%) in the revision augmentation cohort through 10 years. There were five cases of fibrocystic disease in the revision-augmentation cohort through 10 years (1.8%).

There were no cases of BIA-ALCL in any of the patient cohorts.

### Connective Tissue Disease

Among primary augmentation patients, through Year 10, eleven patients have reported 12 confirmed CTDs. The diagnoses include: one patient with chronic fatigue syndrome (diagnosed 9 months post implantation); two patients with fibromyalgia (diagnosed 9 months and 5.6 years post implantation); one patient with Grave's disease (diagnosed 4.1 years post implantation); one patient with lupus (diagnosed 2.3 years post implantation); two patients with Raynaud's Phenomenon (diagnosed at 9 months and 5.3 years post implantation); four cases of rheumatoid arthritis (diagnosed between 2 months and 6.1 years post implantation); and one patient with Sjögren's syndrome (diagnosed 6.8 years post implantation, who also had a confirmed implant rupture). The 10-year risk of a Primary Augmentation patient diagnosed with any CTD is 1.2%.

Among revision-augmentation patients, through Year 10, three patients have reported confirmed CTDs, and none of these patients

had confirmed ruptures. The diagnoses include: one patient with fibromyalgia (diagnosed 10 months post implantation); one patient with Grave's disease (diagnosed 8.34 years post implantation); and one patient with scleroderma (diagnosed 8.01 years post implantation). The 10-year risk of a Revision Augmentation patient diagnosed with any CTD is 1.3%.

### CTD Signs and Symptoms

In Sientra's Study, self-reported CTD signs and symptoms were collected. Patients were asked about various signs/symptoms (e.g., malar rash, alopecia, muscle weakness, myalgias, arthralgias, morning stiffness, arthritis, migraine headaches, hemiplegia, ataxia, seizures, muscle weakness, chronic malaise). Compared to before having implants, for the pooled primary augmentation and revision-augmentation cohorts, no significant increases were found in any of the 13 CTD sign/symptom categories (skin, muscle, joint, neurologic, pain, fatigue, fibromyalgia, gastrointestinal, EENT, hematologic, constitutional, endocrine/exocrine, and vascular).

Conversely, compared to before having implants, significant decreases were found for 3 of the 13 CTD sign/symptom categories: neurological, endocrine/exocrine, and vascular. For the category of neurological, the significance is driven by the low number of post-implantation reports of migraine. For the category of endocrine/exocrine, the significance is driven by the low number of post-implantation reports of Hashimoto's thyroiditis, while for the category of vascular the significance is driven by a decrease in telangiectasia post-implantation.

The Sientra Study was not designed to evaluate cause-and-effect associations because there is no comparison group of women without implants, and because other contributing factors, such as medications and lifestyle/exercise, were not studied. Therefore, it cannot be determined whether or not these 3 decreases were due to the Implants.

### Lactation Complications

There were 236 primary augmentation patients experiencing at least one postoperative live birth; of these, 85.0% reported no difficulties with lactation after they received Sientra's Implants. Twenty-seven of the 236 patients (11%) reported postoperative lactation difficulties, such as lack of milk production, mastitis, or pain. In addition, one woman (0.4%) who had experienced preoperative lactation difficulties reported postoperative difficulties as well.



There were 47 revision-augmentation patients experiencing at least one postoperative live birth; of these, 85.1% reported no difficulties with lactation after they received Sientra's Implants. Five of the 47 patients (11%) reported postoperative lactation difficulties, such as lack of milk production or pain.

### Reproduction Complications

Of the 1,116 patients in the primary augmentation cohort, 19 (1.7%) reported postoperative pregnancy difficulties through 10 years. Of the 363 patients in the revision-augmentation cohort, six (1.7%) reported postoperative pregnancy difficulties.

### Suicide

There was one report of suicide in primary augmentation and no reports of suicide in the revision-augmentation patients in the Study through 10 years.

### Risk Factor Analysis

Within the augmentation and revision-augmentation cohorts, five endpoints (capsular contracture, infection, rupture, reoperation, and explantation with or without replacement) were explored using a covariate analysis to evaluate their association with patient age, BMI, device characteristics (shaped/round, smooth/textured, size, years of implantation), and surgical characteristics (incision site, betadine/antibiotic pocket irrigation, submuscular/subglandular, general/local anesthesia, surgical facility). Results from the risk factor analyses are described below.

### Primary Augmentation

Within the augmentation cohort, most of the analyses were not statistically significant. The few significant findings were:

- Lower capsular contracture risk associated with textured devices, submuscular placement, and longer implantation time
- Decreased risk of infection associated with lower BMI and longer implantation time.
- Increased risk of rupture associated with longer implantation time.
- Decreased risk of reoperation and risk of explantation associated with increased implantation time.

### Revision Augmentation

Within the revision-augmentation cohort, infection was not explored because there were too few events and most of the remaining analyses were not statistically significant. The few significant findings were:

- Lower capsular contracture risk associated with younger age at implantation and longer implantation time.
- Decreased risk of reoperation and risk of explantation associated with increased implantation time; this indicates that these events (as well as capsular contracture) were more likely to occur early rather than near the end of this 10-year study.

## PRIMARY RECONSTRUCTION AND REVISION-RECONSTRUCTION PATIENTS

## PATIENT ACCOUNTING AND FOLLOW-UP RATES

The Study enrolled 225 primary reconstruction patients, which includes 152 patients from the CORE clinical study and 73 patients from the Continued Access (CA) study. Of the women expected to be seen at the 10-year follow-up visit, 65% were seen.

The Study enrolled 84 revision-reconstruction patients, which includes 52 patients from the CORE clinical study and 32 patients from the CA study. Of the women expected to be seen at the 10-year follow-up visit, 58% were seen.

## EFFECTIVENESS OUTCOMES

The benefits of Sientra Silicone Gel Breast Implants were determined by assessing patient satisfaction using patient-reported quality-of-life (QOL) outcomes, including the Short Form Health Survey (SF-36), the Rosenberg Self-Esteem Scale, and the Body Image Scale. The information was collected before implantation and at scheduled follow-up visits.

### Primary Reconstruction Patients

The majority of primary reconstruction patients in this Study were satisfied with their results. The Study showed that most women felt their breast implants make them feel more feminine (77%) and more attractive (71%). In addition, the majority of women indicated that their breast implants made them feel better about themselves (69%).

For primary reconstruction patients, comparison of baseline QOL scores to scores at Year 10 showed a number of statistically significant decreases in the quality-of-life scales (decreases ranged from -1.2 to -6.3 within the 0-100 point-scales, and effect sizes ranged between 0.01-0.48). Statistical significance was defined as those with an Effect Size >0.20 and p-value <0.05 (using a GEE model).



For primary reconstruction patients, mean total scores on the Rosenberg Self-Esteem Scale at Baseline and Year 10 remained above 25. Scores between 15 and 25 are considered to be within normal range, with higher scores indicating more positive feelings.

Mean scores for the Body Esteem Scale and subscales (physical condition, sexual attractiveness, and weight concern) showed no statistically significant changes from Baseline to Year 10 among women in the primary reconstruction cohort.

### Revision-Reconstruction Patients

The majority of revision-reconstruction patients in this Study were satisfied with their results. The Study showed that most women felt their breast implants made them feel more feminine (92%) and feel more attractive (84%). In addition, the majority of women indicated that their breast implants made them feel better about themselves (85%).

For the revision-reconstruction patients, baseline QOL scores to scores at Year 10 showed no statistically significant changes. Statistical significance was defined as those with an Effect Size >0.20 and p-value <0.05 (using a GEE model).

For revision-reconstruction patients, mean total scores on the Rosenberg Self-Esteem Scale at Baseline and Year 10 remained above 25. Scores between 15 and 25 are considered to be within normal range, with higher scores indicating more positive feelings.

Scores for the Body Esteem Scale and subscales (physical condition, sexual attractiveness and weight concern) showed no statistically significant changes from Baseline to Year 10 among women in the revision-reconstruction cohort.

## SAFETY OUTCOMES

The safety of Sientra's Silicone Gel Breast Implants was determined by assessing the incidence of complications, including device failures.

### Primary Reconstruction Patients

Table 17 describes the Kaplan-Meier risk of complications for the primary reconstruction patients in the Study.

**Table 17. Kaplan-Meier Risk of Complications for Primary Reconstruction Patients (N=225 Patients)**

| Key Complications | 3-yr KM Risk (95% CI) | 6-yr KM Risk (95% CI) | 10-yr KM Risk (95% CI) |
|---|---|---|---|
| Reoperation | 35.6% (29.6%, 42.4%) | 43.4% (36.9%, 50.4%) | 48.2% (41.5%, 55.4%) |
| Implant Removal with Replacement | 18.8% (14.0%, 24.9%) | 24.8% (19.3%,31.5%) | 28.8% (22.8%, 35.9%) |
| Implant Rupture (MRI cohort)[1] | 0% | 2.8% (0.4%,18.1%) | 16.5% (6.3%, 39.1%) |
| Capsular Contracture (Baker Grade III/IV) | 9.7% (6.3%, 14.9%) | 11.7% (7.8%, 17.2%) | 15.8% (11.0%, 22.5%) |
| Implant Removal without Replacement | 6.5% (3.9%, 10.8%) | 8.5% (5.3%, 13.3%) | 11.1% (7.2%, 17.1%) |
| **Other Complications Occurring at a KM Risk ≥1%[2,3]** | | | |
| Asymmetry | 9.0% (5.7%, 13.9%) | 11.5% (7.7%, 17.0%) | 11.5% (7.7%, 17.0%) |
| Infection | 5.1% (2.9%, 9.1%) | 5.1% (2.9%, 9.1%) | 5.1% (2.9%, 9.1%) |
| Implant Malposition | 3.0% (1.4%, 6.6%) | 5.1% (2.7%, 9.7%) | 5.1% (2.7%, 9.7%) |
| Breast Pain | 3.1% (1.4%, 6.8%) | 3.8% (1.8%, 7.8%) | 4.5% (2.3%, 9.0%) |
| Hypertrophic/Abnormal Scarring | 2.1% (0.8%, 5.6%) | 4.1% (2.0%, 8.4%) | 4.1% (2.0%, 8.4%) |
| Seroma/Fluid Accumulation | 2.4% (1.0%, 5.8%) | 2.4% (1.0%, 5.8%) | 3.6% (1.5%, 8.3%) |
| Ptosis | 2.0% (0.8%, 5.3%) | 3.4% (1.5%, 7.6%) | 3.4% (1.5%, 7.6%) |
| Breast Mass/Cyst/Lump | 1.0% (0.3%, 4.1%) | 2.9% (1.2%, 6.8%) | 2.9% (1.2%, 6.8%) |
| Redness | 2.6% (1.1%, 6.1%) | 2.6% (1.1%, 6.1%) | 2.6% (1.1%, 6.1%) |
| Nipple Sensation Changes | 0.6% (0.1%, 3.8%) | 2.5% (1.0%, 6.7%) | 2.5% (1.0%, 6.7%) |
| Wrinkling/Rippling | 1.1% (0.3%, 4.2%) | 2.3% (0.9%, 6.2%) | 2.3% (0.9%, 6.2%) |
| Implant Extrusion | 1.5% (0.5%, 4.5%) | 2.1% (0.8%, 5.5%) | 2.1% (0.8%, 5.5%) |
| Delayed Wound Healing | 1.9% (0.7%, 5.0%) | 1.9% (0.7%, 5.0%) | 1.9% (0.7%, 5.0%) |
| Swelling | 1.5% (0.5%, 4.7%) | 1.5% (0.5%, 4.7%) | 1.5% (0.5%, 4.7%) |
| Implant Palpability | 0.5% (0.1%, 3.2%) | 0.5% (0.1%, 3.2%) | 1.3% (0.3%, 5.2%) |
| Upper Pole Fullness | 0.6% (0.1%, 3.8%) | 1.2% (0.3%, 4.9%) | 1.2% (0.3%, 4.9%) |
| Hematoma | 0.4% (0.1%, 3.1%) | 1.1% (0.3%, 4.4%) | 1.1% (0.3%, 4.4%) |
| Implant Visibility | 1.0% (0.3%, 4.1%) | 1.0% (0.3%, 4.1%) | 1.0% (0.3%, 4.1%) |
| **Composite Category** | | | |
| Any Complications | 44.6% (38.1%, 51.5%) | 62.4% (55.0%, 69.9%) | 64.3% (57.5%, 71.0%) |

1. At 10 years, implant rupture was reported at a risk rate of 0%, 1.5% (0.2%, 9.8%) and 6.6% (2.1%, 19.3%) at the 3-year, 6-year, and 10-year timepoints, respectively in the non-MRI cohort.
2. The following complications were reported at a risk rate of less than 1% through ten years: nipple complications (not related to sensation), skin rash, skin sensation changes and other complications.
3. None of the following complications were reported: bruising, capsule calcification, irritation, lymphadenopathy, lymphedema, necrosis, and pneumothorax.

## Revision-Reconstruction Patients

Table 18 describes the Kaplan-Meier risk of complications for the revision-reconstruction patients in the Study.

**Table 18. Kaplan-Meier Risk of Complications Reported for Revision-Reconstruction Patients through 10 Years (N=84 Patients)**

| Key Complications | 3-yr KM Risk (95% CI) | 6-yr KM Risk (95% CI) | 10-yr KM Risk (95% CI) |
|---|---|---|---|
| Reoperation | 39.4% (29.5%, 51.1%) | 46.3% (35.9%, 58.0%) | 56.7% (45.4%, 68.5%) |
| Implant Removal with Replacement | 20.0% (12.5%, 31.0%) | 26.0% (17.4%, 37.8%) | 40.5% (29.1%, 54.4%) |
| Implant Removal without Replacement | 10.8% (5.5%, 20.6%) | 14.3% (7.9%, 25.1%) | 18.9% (11.0%, 31.6%) |
| Capsular Contracture (Baker Grade III/IV) | 7.9% (3.6%, 16.8%) | 12.1% (6.1%, 23.2%) | 14.3% (7.5%, 26.4%) |
| Implant Rupture (MRI cohort)[1] | 0% | 0% | -- |
| **Other Complications Occurring at a KM Risk ≥1%[2]** | | | |
| Asymmetry | 11.1% (5.7%, 21.1%) | 14.7% (8.1%, 25.9%) | 16.9% (9.6%, 28.8%) |

**Table 18. Kaplan-Meier Risk of Complications Reported for Revision-Reconstruction Patients through 10 Years (N=84 Patients)**

| Key Complications | 3-yr KM Risk (95% CI) | 6-yr KM Risk (95% CI) | 10-yr KM Risk (95% CI) |
|---|---|---|---|
| Implant Malposition | 6.5% (2.8%, 15.0%) | 8.4% (3.8%, 18.1%) | 11.5% (5.3%, 23.9%) |
| Breast Mass/Cyst/Lump | 2.9% (0.7%, 11.0%) | 4.6% (1.5%, 13.7%) | 4.6% (1.5%, 13.7%) |
| Breast Pain | 1.3% (0.2%, 8.9%) | 3.1% (0.8%, 11.9%) | 3.1% (0.8%, 11.9%) |
| Hypertrophic/Abnormal Scarring | 2.9% (0.7%, 11.0%) | 2.9% (0.7%, 11.0%) | 2.9% (0.7%, 11.0%) |
| Wrinkling/Rippling | 2.9% (0.7%, 11.2%) | 2.9% (0.7%, 11.2%) | 2.9% (0.7%, 11.2%) |
| Nipple Sensation Changes | 0% | 0% | 2.3% (0.3%, 15.1%) |
| Infection | 1.2% (0.2%, 8.3%) | 1.2% (0.2%, 8.3%) | 1.2% (0.2%, 8.3%) |
| Seroma/Fluid Accumulation | 1.2% (0.2%, 8.3%) | 1.2% (0.2%, 8.3%) | 1.2% (0.2%, 8.3%) |
| **Composite Category** | | | |
| Any Complications | 43.2% (32.8%, 55.4%) | 60.9% (49.3%, 72.8%) | 68.8% (57.6%, 79.4%) |

1. No ruptures were reported in the revision-reconstruction MRI cohort; however, 5 patients (2 confirmed and 3 unconfirmed) were reported as ruptures in the non-MRI cohort.
2. None of the following complications were reported: bruising, capsule calcification, delayed wound healing, hematoma, implant extrusion, implant palpability, implant visibility, irritation, lymphadenopathy, lymphedema, necrosis, nipple complications (not related to sensation), pneumothorax, ptosis, redness, skin rash, skin sensation changes, swelling, upper pole fullness and other complications.

## REASONS FOR REOPERATION

### Primary Reconstruction Patients

There were 124 reoperations performed in 99 primary reconstruction patients through 10 years following implantation. Table 19 provides the main reasons for reoperation in the primary reconstruction cohort at 3, 6, and 10 years. In this population, the most common reason for reoperation, through 10 years, was the patient's desire for a change in the style or size of the implant (20%).

**Table 19. Main Reasons for Reoperation At Timepoints Through 10 Years For Primary Reconstruction Patients**

| Main Reasons* for Reoperation | Through 3 Years Reoperations= 85 Patients = 74 n (%) | Through 6 Years Reoperations = 109 Patients = 91 n (%) | Through 10 Years Reoperations= 124 Patients = 99 n (%) |
|---|---|---|---|
| Suspected Rupture | 1 (1.2%) | 2 (1.8%) | 5 (4.0%)** |
| Infection | 10 (11.8%) | 10 (9.2%) | 10 (8.1%) |
| Capsular Contracture | 7 (8.2%) | 8 (7.3%) | 9 (7.3%) |
| Healing Related | | | |
| Extrusion | 2 (2.4%) | 2 (1.8%) | 2 (1.6%) |
| Necrosis | 0 (0%) | 0 (0%) | 0 (0%) |
| Hematoma/Seroma | 3 (3.5%) | 5 (4.6%) | 5 (4.3%) |
| Delayed Wound Healing | 3 (3.5%) | 3 (2.8%) | 3 (2.4%) |
| Irritation/Inflammation | 0 (0%) | 0 (0%) | 0 (0%) |
| Pain | 0 (0%) | 0 (0%) | 1 (0.8%) |
| Cosmetic | | | |
| Malposition | 4 (4.7%) | 6 (5.5%) | 7 (5.6%) |
| Upper Pole Fullness | 0 (0%) | 0 (0%) | 0 (0%) |
| Wrinkling/Rippling | 0 (0%) | 0 (0%) | 1 (0.8%) |
| Palpability/Visibility | 1 (1.2%) | 1 (0.9%) | 1 (0.8%) |
| Asymmetry | 16 (18.8%) | 19 (17.4%) | 20 (16.1%) |
| Ptosis | 5 (5.9%) | 7 (6.4%) | 7 (5.6%) |
| Scarring/Hypertrophic Scarring | 3 (3.5%) | 4 (3.7%) | 4 (3.2%) |
| Nipple Related | 1 (1.2%) | 5 (4.6%) | 5 (4.0%) |
| Breast Cancer | 0 (0%) | 1 (0.9%) | 3 (2.4%) |
| Mass/Lump/Cyst | 4 (4.7%) | 5 (4.6%) | 6 (4.8%) |
| Skin Related | 1 (1.2%) | 1 (0.9%) | 2 (1.6%) |
| Style/Size Change | 21 (24.7%) | 24 (22.0%) | 25 (20.2%) |
| Trauma | 0 (0%) | 0 (0%) | 0 (0%) |
| Unknown | 3 (3.5%) | 6 (5.5%) | 8 (6.5%) |

*Some reoperations were performed for multiple reasons; only the primary reason is provided in the table.
** Two of the five patients were confirmed non-ruptured via explant.

### Revision-Reconstruction Patients

There were 55 reoperations performed in 42 revision-reconstruction patients through 10 years following implantation. Table 20 provides the main reasons for reoperation in the revision-reconstruction cohort at 3, 6, and 10 years. In this population, the most common reasons for reoperation through 10 years was asymmetry (24%).

**Table 20. Main Reasons for Reoperation At Timepoints Through 10 Years For Revision Reconstruction Patients**

| Main Reasons* for Reoperation | Through 3 Years Reoperations = 38 Patients = 31 n (%) | Through 6 Years Reoperations= 46 Patients = 36 n (%) | Through 10 Years Reoperations = 55 Patients = 42 n (%) |
|---|---|---|---|
| Suspected Rupture | 0 (0%) | 0 (0%) | 1 (1.8%) |
| Infection | 1 (2.6%) | 1 (2.2%) | 1 (1.8%) |
| Capsular Contracture | 6 (15.8%) | 8 (17.4%) | 12 (21.8%) |
| Healing Related | | | |
| Extrusion | 0 (0%) | 0 (0%) | 0 (0%) |
| Necrosis | 0 (0%) | 0 (0%) | 0 (0%) |
| Hematoma/Seroma | 1 (2.6%) | 1 (2.2%) | 1 (1.8%) |
| Delayed Wound Healing | 0 (0%) | 0 (0%) | 0 (0%) |
| Irritation/Inflammation | 0 (0%) | 0 (0%) | 0 (0%) |
| Pain | 1 (2.6%) | 2 (4.3%) | 2 (3.6%) |
| Cosmetic | | | |
| Malposition | 4 (10.5%) | 5 (10.9%) | 5 (9.1%) |
| Upper Pole Fullness | 0 (0%) | 0 (0%) | 0 (0%) |
| Wrinkling/Rippling | 1 (2.6%) | 1 (2.2%) | 1 (1.8%) |
| Palpability/Visibility | 0 (0%) | 0 (0%) | 0 (0%) |
| Asymmetry | 9 (23.7%) | 9 (19.6%) | 13 (23.6%) |
| Ptosis | 0 (0%) | 0 (0%) | 0 (0%) |
| Scarring/Hypertrophic Scarring | 0 (0%) | 1 (2.2%) | 1 (1.8%) |
| Nipple Related | 1 (2.6%) | 3 (6.5%) | 3 (5.5%) |
| Breast Cancer | 1 (2.6%) | 1 (2.2%) | 1 (1.8%) |
| Mass/Lump/Cyst | 2 (5.3%) | 2 (4.3%) | 2 (3.6%) |
| Skin Related | 0 (0%) | 0 (0%) | 0 (0%) |
| Style/Size Change | 10 (26.3%) | 9 (19.6%) | 9 (16.4%) |
| Trauma | 1 (2.6%) | 1 (2.2%) | 1 (1.8%) |
| Unknown | 0 (0%) | 2 (4.3%) | 2 (3.6%) |

* Some reoperations were performed for multiple reasons; only the primary reason is provided in the table.

## REASONS FOR IMPLANT REMOVAL

### Primary Reconstruction Patients

The main reasons for explantation among primary reconstruction patients through 10 years are provided in Table 21. There were 111 implants removed from 73 patients. Of these 111 implants, most were replaced (77%). The most common reason for implant removal was the patient requested an implant style or size change (36%).

**Table 21. Main Reason for Implant Removal Through 10 Years for Primary Reconstruction Patients (N=111 Explants)**

| Reasons for Implant Removal | n (%) |
|---|---|
| Patient Request for Size/Style Change | 40 (36.0%) |
| Asymmetry | 18 (16.2%) |
| Unknown | 11 (9.9%) |
| Implant Malposition | 9 (8.1%) |
| Infection | 9 (8.1%) |
| Capsular Contracture | 8 (7.2%) |
| Suspected Rupture[1] | 6 (5.4%) |
| Scarring/Hypertrophic Scarring | 3 (2.7%) |
| Implant Extrusion | 2 (1.8%) |
| Wrinkling/Rippling | 2 (1.8%) |
| Breast Cancer | 1 (0.9%) |
| Delayed Wound Healing | 1 (0.9%) |
| Hematoma/Seroma | 1 (0.9%) |

1. Two of the 5 patients were confirmed non-ruptured at explantation for the combined MRI and non-MRI cohort.

### Revision-Reconstruction Patients

The main reasons for explantation among revision-reconstruction patients through 10 years are provided in Table 22. There were 50 implants removed from 36 patients. Of these 50 implants, most were replaced (72%). The most common reason for implant removal was the patient requested an implant style or size change (28%).

**Table 22. Main Reason for Implant Removal through 10 Years for Revision-Reconstruction Patients (N=50 Explants)**

| Reasons for Implant Removal | n (%) |
|---|---|
| Patient Request for Size/Style Change | 14 (28.0%) |
| Asymmetry | 9 (18.0%) |
| Capsular Contracture | 9 (18.0%) |
| Implant Malposition | 4 (8.0%) |
| Pain | 4 (8.0%) |
| Unknown | 3 (6.0%) |
| Trauma | 2 (4.0%) |
| Breast Cancer | 1 (2.0%) |
| Hematoma/Seroma | 1 (2.0%) |
| Infection | 1 (2.0%) |
| Wrinkling/Rippling | 1 (2.0%) |

## OTHER CLINICAL FINDINGS

The Study evaluated several long-term health effects that had been previously reported in breast implant patients. These include rupture, cancer, connective tissue disease (CTD), CTD signs and symptoms, lactation complications, reproduction complications and suicide.

### Cancer

One primary reconstruction patient reported breast cancer during the 10 years following implantation and 3 recurrent cases of breast cancer were reported (2.9%). Diagnoses of any other (non-breast) cancers have been reported in 16 patients (7.1%) in the primary reconstruction cohort through 10 years. The other types of cancer include duodenum, ovarian, pancreatic, skin, and metastatic cancers. There were no reports of fibrocystic breast disease reported through 10 years in primary reconstruction patients.

Two revision-reconstruction patients reported breast cancer through 10 years in the Study. This represents a risk of 3.2%. Diagnoses of any other (non-breast) cancers have been reported in seven patients (8%) in the revision-reconstruction cohort through 10 years. The other types of cancers reported in the revision-reconstruction cohort include lung, skin, and metastatic cancers. There was one report of fibrocystic disease among revision-reconstruction patients through 10 years (1.7%).

There were no cases of BIA-ALCL in any of the patient cohorts.



### Connective Tissue Disease (CTD)

Among primary reconstruction patients through Year 10, one patient has been diagnosed with CTD, Sjögren's Syndrome (5.1 years post-implantation). Based on this, the 10-year risk among primary reconstruction patients of Sjögren's Syndrome is 0.7%.

Two of the 84 revision-reconstruction patients in the Study were diagnosed with a CTD in the 10 years after receiving implants; the diagnoses were one case of Hashimoto's Thyroiditis (1.1-year post implantation) and one case of Sjögren's Syndrome (3.7 years post-implantation, who also had a confirmed implant rupture). Based on this, the 10-year risk of Hashimoto's Thyroiditis is 1.4% while the risk of Sjögren's Syndrome is 1.8%, while the risk of having at least one CTD is 3.2%

### CTD Signs and Symptoms

In Sientra's Clinical Study, numerous self-reported CTD signs and symptoms were collected. Compared to before having implants, for the pooled primary reconstruction and revision-reconstruction cohorts, no significant increases or decreased were found across the 13 sign/symptom categories.

The Sientra Study was not designed to evaluate cause-and-effect associations because there is no comparison group of women without implants, and because other contributing factors, such as medications and lifestyle/exercise, were not studied.

### Lactation Complications

There were 22 primary reconstruction patients who delivered a baby after reconstruction with Study Implants. There were three revision-reconstruction patient who delivered a baby after reconstruction with Study Implants; these patients reported no problems with lactation.

None of the primary and revision reconstruction patients reported difficulties with lactation after they received the Implants; however, it was not reported if they attempted breastfeeding on the reconstructed breast or on the contralateral side.

### Reproduction Complications

Of the 225 patients in the primary reconstruction cohort, 2 (0.9%) reported postoperative difficulties through 10 years. Of the 84 patients in the revision-reconstruction cohort, none (0%) reported postoperative difficulties.

### Suicide

There were no reports of suicide in primary reconstruction or revision-reconstruction patients in the Study through 10 years.

### Other Deaths

During the course of the 10-year Sientra Clinical Study, data on subject deaths was collected and is summarized below in Table 23:

**Table 23. Other Deaths - 10 Year Clinical Study**

| Reported Cause of Death | Primary Augmentation | Revision Augmentation | Primary Reconstruction | Revision Reconstruction |
|---|---|---|---|---|
| Accidental Combined Drug Intoxication | 1 | | | |
| Acute Hemolysis Syndrome | | 1 | | |
| Blood Clots in Legs | | | 1 | |
| Cancer (Unknown Type) | 1 | | 2 | |
| Cancer, Lung | 1 | 1 | | |
| Cancer, Metastatic* | | | 5 | 4 |
| Cancer, Ovarian | | | 1 | |
| Cancer, Pancreatic | | | 1 | |
| Cancer, Uterine | | | 1 | |
| Coronary Thrombus | | 1 | | |
| Heart Attack (As reported) | | 1 | | |
| Injury due to Hurricane (Unconfirmed) | 1 | | | |
| Multiple Substance Intoxication | 1 | | | |
| Myelodysplastic Syndrome | | | 1 | |
| Possible Suicide | 1 | | | |
| Pulmonary Embolism | 1 | | | |
| Unknown | 3 | | 3 | 4 |

*Reported cases of metastatic cancer in the primary reconstruction cohort include the following: one patient with metastatic bone and brain cancer, one patient with metastatic brain cancer, one patient with metastatic bone and lymph node cancer, one patient with metastatic spinal and femur cancer and one patient with metastatic spinal cancer. The reported cases of metastatic cancer in the revision-reconstruction cohort include one patient with metastatic brain cancer, one patient with metastatic shoulder, spinal, brain, lung and liver cancer, one patient with metastatic lung cancer and one patient with metastatic breast cancer (unknown type).



### Risk Factor Analysis

Within the reconstruction and revision-reconstruction cohorts, five endpoints (capsular contracture, infection, rupture, reoperation, and explantation with or without replacement) were explored using a covariate analysis to evaluate their association with patient age, BMI, device characteristics (shaped/round, smooth/textured, size, years of implantation), and surgical characteristics (incision site, betadine/antibiotic pocket irrigation, submuscular/subglandular, general/local anesthesia, surgical facility).

### Primary Reconstruction

Within the reconstruction cohort, most of the analyses were not statistically significant. Only one factor was found to be significant: implantation time. The analysis found that four of the explored events (capsular contracture, infection, reoperation and explantation) were more likely to occur early rather than near the end of this 10-year study. Rupture was not explored because there were too few events.

### Revision-Reconstruction

Within the revision-reconstruction cohort, infection and rupture were not explored because there were too few events and most of the remaining analyses were not statistically significant. The analysis found that for capsular contracture, risk of reoperation and risk of explantation were more likely to occur early rather than near the end of this 10-year study.

### National Breast Implant Registry

In collaboration with the U.S. Food and Drug Administration (FDA) and breast implant device manufacturers, The Plastic Surgery Foundation (PSF) has developed the National Breast Implant Registry (NBIR) for the purpose of strengthening national surveillance for breast implant devices in the United States. The NBIR is a prospective, non-interventional, population-based, outcomes and safety surveillance registry and quality improvement initiative. The NBIR collects clinical, procedural and outcomes data at the time of operation and any subsequent reoperations. Data collection is anticipated to continue as long as breast implants are being manufactured. The NBIR is currently only open to physicians practicing in the United States.

If your patient agrees to participate in the NBIR, you can use the registry to submit device tracking data to the breast implant manufacturers by completing the NBIR case report form (CRF). If your

patient does not want to participate in the NBIR, you cannot use the registry for device tracking and will need to use the paper device tracking form that is in the implant box.

To learn more about the NBIR go to the following link:

https://www.thepsf.org/documents/Research/Registries/NBIR/nbir-physician-faq.PDF

# INSTRUCTIONS FOR USE

**Back-up Implants should be available during the procedure.**

**Do not use more than one implant per breast.**

**The product is intended for single use only. Do not reuse explanted implants.**

## PREOPERATIVE PATIENT PROCEDURES

Sientra relies on the surgeon to know and follow proper surgical procedures when implanting, explanting, or performing revising surgery with Sientra's Implants. Proper surgical planning, such as allowance for adequate tissue coverage, implant placement, incision site, implant size, shape, style, and texture, should be made preoperatively. The surgeon should take into consideration the contraindications, warnings and precautions described in this document, as well as the patient's medical history, desires, and expectations, and physical condition.

## INSTRUCTIONS FOR OPENING AND INSPECTING THE STERILE PACKAGE

1. Examine the implant's sealed outer box before entering the surgical area to verify package integrity. **Do not utilize any implant with packaging that appears to be damaged in any way.**
2. Open the outer box and remove the interior double blister packaging.
3. Separate the product accessories, such as the Instructions for Use, the Device Identification Card, Breast Implant Tracking Form, and the adhesive labels.
4. Attach the adhesive labels with the product data to the patient's operative report and patient Device Identification (ID) Card. Make sure to provide the Device ID card to the patient after surgery.
5. Open the outer blister package to gain access to the inner sterile blister packaging, taking care not to contaminate the inner sterile blister packaging by touching it to the outside of the outer blister.
6. Open the sterile inner blister package being careful to avoid contact with dust, lint, and talc, and place the implant onto the surgical tray.

Do not implant any device that

- Appears to have particulate contamination, damage, or loss of shell integrity,
- Appears to have leaks or nicks, or
- Is damaged or contaminated.

The Sientra Implants are sterilized by dry heat. Do not re-sterilize the product**.**

## INTRAOPERATIVE CONSIDERATIONS

Take note of the following intraoperative considerations:

- Have a spare Implant available during the surgical procedure and all follow-up procedures, revisions, and capsulotomies.
- The periumbilical approach has not been studied in Sientra's Study and should not be used for a variety of reasons, including potential damage to the implant shell.
- To avoid damaging the device, ensure that the incision is sufficiently large to facilitate insertion without excessive manipulation and handling of the device.

Do not use lubricants to facilitate placement.

Use extreme care to avoid damaging the breast implant with sharp surgical instruments such as needles and scalpels, or with cautery devices or blunt instruments such as clamps or forceps, or by over handling and manipulation during introduction into the surgical pocket.

Do not use excessive force during breast implant placement.

Please refer to the *Warnings* and *Precautions* sections in this document for additional information about intraoperative considerations.

### POSTOPERATIVE CONSIDERATIONS

Postoperative hematoma and seroma may be minimized by meticulous attention to hemostasis during surgery, and possibly also by postoperative use of a closed drainage system. Persistent, excessive bleeding must be controlled before implantation. Any postoperative evacuation of hematoma or seroma must be conducted with care to avoid damage to the implant from sharp instruments.

## MANAGING A RUPTURED IMPLANT

Physicians should recommend implant removal to their patients if a rupture is confirmed.

In the event of rupture of a breast implant, the following technique is useful for removal of the silicone mass. Wearing double talc-free surgical gloves on one hand, use the index finger to penetrate the silicone mass. With the other hand, exert pressure on the breast to facilitate manipulation of the silicone mass into the double-gloved hand. Once the silicone is in hand, pull the outer glove over the silicone mass and remove. To remove any residual silicone, blot the surgical pocket with gauze sponges. Avoid contact between surgical instruments and the silicone. If contact occurs, use isopropyl alcohol to remove the silicone from the instruments. Ruptured breast implants must be reported and should be returned to Sientra in an Explant Return Kit. In the event of breast implant rupture, contact Sientra at (888) 708-0808.

## ADDITIONAL PRODUCT-SPECIFIC INFORMATION

### RETURNED MERCHANDISE POLICY

Product returns should be processed through a Sientra Sales Representative or through the Sientra Customer Experience Team at (888) 708-0808. All package seals must be intact to be eligible for return.



### EXPLANTED DEVICE RETURNS AND REPORTING

Explanted devices must be returned to Sientra and the reason for explantation must be provided. All explanted devices must be returned in a Sientra Explant Return Kit. Please contact the Sientra Customer Experience Team at (888) 708-0808 for a Sientra Explant Return Kit and instructions.

### PRODUCT REPLACEMENT POLICY AND LIMITED WARRANTIES

The Sientra Platinum20™ Limited Warranty and Lifetime Product Replacement Program provides lifetime replacement and limited financial reimbursement in the event of shell leakage or breakage resulting in implant rupture, or complications of capsular contracture Baker Grade III/IV, double capsule, late forming seromas and BIA-ALCL, subject to certain conditions as discussed in the Sientra Platinum20 Limited Warranty literature. Our standard Platinum20 Limited Warranty program applies to every Sientra breast implant recipient subject to their participation in Sientra's Device Tracking program and to the conditions discussed in the Sientra Platinum20 Limited Warranty literature. For more information, please contact Sientra Customer Service at (888) 708-0808.

### PRODUCT ORDERING

To order directly in the U.S.A. or for product information, please contact Sientra's Customer Experience Team at (888) 708-0808.

### ACCESS TO ELECTRONIC INFORMATION

The *Patient Educational Brochures*, *Patient Decision Checklist,* and *Device Tracking Form* can be found on Sientra's website at www.Sientra.com. The electronic version of this IFU can also be found on Sientra's website.

### REPORTING PROBLEMS

The U.S. Food and Drug Administration requires healthcare providers to report serious injuries involving medical devices (defined as those that need medical or surgical intervention to prevent permanent damage) to the manufacturer and/or to FDA. In addition, injuries or complications can be voluntarily reported directly by the patient to FDA's MedWatch.

If you have a patient who has experienced one or more serious problems related to her breast implants, you are encouraged to report the serious problem(s) to FDA through the MedWatch voluntary reporting system for her. Examples of serious problems include disability, hospitalization, harm to offspring, and medical or surgical intervention to prevent lasting damage.

You are also required to report any product problem or serious adverse effect to Sientra. Deaths must be reported to Sientra and FDA. You can report by telephone to 1-800-FDA-1088 (1-800-332-1088); by FAX, use Form 3500 to 1-800-FDA-0178 (1-800-332-0178); electronically at http://www.fda.gov/medwatch/index.html; or by mail to MedWatch Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857-9787. Keep a copy of the completed MedWatch form for your records.

This information reported to MedWatch is entered into databases to be used to follow safety trends and to determine whether further follow up of any potential safety issues related to the device is needed.

## DEVICE MANUFACTURER

Sientra's Silicone Gel Breast Implants are manufactured for and sold by:

Sientra, Inc.
3333 Michelson Drive, Suite 650, Irvine, CA 92612

U.S. Toll-Free Phone: (888) 708-0808
Phone: (805) 562-3500
Fax: (805) 562-8401

www.sientra.com



## REFERENCES


1. FDA, *Tracking obligations of persons other than device manufacturers: distributor requirements. 21 Code of Federal Regulations (CFR) §821.30* 2010.
2. Bondurant, S., V.L. Ernster, and R. Herdman, *Safety of Silicone Breast Implants. Committee on the Safety of Silicone Breast Implants, Division of Health Promotion and Disease Prevention, Institute of Medicine*. 2000, Washington, D.C.: National Academy Press.
3. Henriksen, T.F., et al., *Surgical intervention and capsular contracture after breast augmentation: a prospective study of risk factors.* Ann Plast Surg, 2005. **54**(4): p. 343-51.
4. Kulmala, I., et al., *Local complications after cosmetic breast implant surgery in Finland.* Ann Plast Surg, 2004. **53**(5): p. 413-9.
5. Bleiweiss, I.J., M.J. Klein, and M. Copeland, *Breast prosthesis reaction.* Am J Surg Pathol, 1996. **20**(4): p. 505-7.
6. *American Academy of Pediatrics (AAP) Committee on Drugs. (2001) Transfer of drugs and other chemicals into human milk. Pediatrics*. ***108***: p. 776-789.
7. Sturrock, R.D. and H. Great Britain. Department of, *Silicone gel breast implants : the report of the Independent Review Group*. 1998, London: London : the Group.
8. Pinsolle, V., et al., *Complications analysis of 266 immediate breast reconstructions.* J Plast Reconstr Aesthet Surg, 2006. **59**(10): p. 1017-24.
9. Whitfield, G.A., et al., *Incidence of severe capsular contracture following implant-based immediate breast reconstruction with or without postoperative chest wall radiotherapy using 40 Gray in 15 fractions.* Radiother Oncol, 2009. **90**(1): p. 141-7.
10. Kronowitz, S.J. and G.L. Robb, *Radiation therapy and breast reconstruction: a critical review of the literature.* Plast Reconstr Surg, 2009. **124**(2): p. 395-408.
11. Destouet, J.M., et al., *Screening mammography in 350 women with breast implants: prevalence and findings of implant complications.* AJR Am J Roentgenol, 1992. **159**(5): p. 973-8; discussion 979-81.
12. Park, A.J., et al., *The detection of breast implant rupture using ultrasound.* Br J Plast Surg, 1996. **49**(5): p. 299-301.
13. Berg, W.A., et al., *Single- and double- lumen silicone breast implant integrity: prospective evaluation of MR and US criteria.* Radiology, 1995. **197**(1): p. 45-52.

14. Brown, S.L., H.J. Duggirala, and G. Pennello, *An association of silicone-gel breast implant rupture and fibromyalgia.* Curr Rheumatol Rep, 2002. **4**(4): p. 293-8.

15. Brown, S.L., et al., *Silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women.* J Rheumatol, 2001. **28**(5): p. 996-1003.

16. Gaubitz, M., et al., *Silicone breast implants: correlation between implant ruptures, magnetic resonance spectroscopically estimated silicone presence in the liver, antibody status and clinical symptoms.* Rheumatology (Oxford), 2002. **41**(2): p. 129-35; discussion 123-4.

17. Hölmich, L.R., et al., *Self-reported diseases and symptoms by rupture status among unselected Danish women with cosmetic silicone breast implants.* Plast Reconstr Surg, 2003. **111**(2): p. 723-32; discussion 733-4.

18. Hölmich, L.R., et al., *Untreated silicone breast implant rupture.* Plast Reconstr Surg, 2004. **114**(1): p. 204-14; discussion 215-6.

19. Hölmich, L.R., et al., *Prevalence of silicone breast implant rupture among Danish women.* Plast Reconstr Surg, 2001. **108**(4): p. 848-58; discussion 859-63.

20. Tzur, R., et al., *Desmoid Tumor and Silicone Breast Implant Surgery: Is There Really a Connection? A Literature Review.* Aesthetic Plast Surg, 2018. **42**(1): p. 59-63.

21. Balzer, B.L. and S.W. Weiss, *Do biomaterials cause implant-associated mesenchymal tumors of the breast? Analysis of 8 new cases and review of the literature.* Hum Pathol, 2009. **40**(11): p. 1564-70.

22. Brinton, L.A., et al., *Risk of connective tissue disorders among breast implant patients.* Am J Epidemiol, 2004. **160**(7): p. 619-27.

23. Hölmich, L.R., et al., *Stage of breast cancer at diagnosis among women with cosmetic breast implants.* Br J Cancer, 2003. **88**(6): p. 832-8.

24. Janowsky, E.C., L.L. Kupper, and B.S. Hulka, *Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases.* N Engl J Med, 2000. **342**(11): p. 781-90.

25. McLaughlin, J.K. and L. Lipworth, *Brain cancer and cosmetic breast implants: a review of the epidemiologic evidence.* Ann Plast Surg, 2004. **52**(2): p. 115-7.

26. Tugwell, P., et al., *Do silicone breast implants cause rheumatologic disorders? A systematic review for a court-appointed national science panel.* Arthritis Rheum, 2001. **44**(11): p. 2477-84.

27. Wolfe, F. and J. Anderson, *Silicone filled breast implants and the risk of fibromyalgia and rheumatoid arthritis.* J Rheumatol, 1999. **26**(9): p. 2025-8.

28. Blackburn, W.D. and M.P. Everson, *Silicone-associated rheumatic disease: an unsupported myth.* Plast Reconstr Surg, 1997. **99**(5): p. 1362-7.

29. Englert, H., et al., *Women's health after plastic surgery.* Intern Med J, 2001. **31**(2): p. 77-89.

30. Fryzek, J.P., et al., *A nationwide study of connective tissue disease and other rheumatic conditions among Danish women with long-term cosmetic breast implantation.* Ann Epidemiol, 2007. **17**(5): p. 374-9.

31. Hochberg, M.C. and D.L. Perlmutter, *The association of augmentation mammoplasty with connective tissue disease, including systematic sclerosis (scleroderma): a meta-analysis.* Curr Top Microbiol Immunol, 1996. **210**: p. 411-7.

32. Kjøller, K., et al., *Connective tissue disease and other rheumatic conditions following cosmetic breast implantation in Denmark.* Arch Intern Med, 2001. **161**(7): p. 973-9.

33. Lamm, S.H., *Silicone Breast Implants, Breast Cancer and Specific Connective Tissue Diseases: A Systematic Review of the Data in the Epidemiological Literature.* International Journal of Toxicology, 1998. **17**(4): p. 497-527.

34. Lewin, S.L. and T.A. Miller, *A review of epidemiologic studies analyzing the relationship between breast implants and connective tissue diseases.* Plast Reconstr Surg, 1997. **100**(5): p. 1309-13.

35. Silverman, B.G., et al., *Reported complications of silicone gel breast implants: an epidemiologic review.* Ann Intern Med, 1996. **124**(8): p. 744-56.

36. Wong, O., *A critical assessment of the relationship between silicone breast implants and connective tissue diseases.* Regul Toxicol Pharmacol, 1996. **23**(1 Pt 1): p. 74-85.

37. Balk, E.M., et al., *Long-Term Health Outcomes in Women With Silicone Gel Breast Implants: A Systematic Review.* Ann Intern Med, 2016. **164**(3): p. 164-75.

38. Coroneos, C.J., et al., *US FDA Breast Implant Postapproval Studies: Long-term Outcomes in 99,993 Patients.* Ann Surg, 2019. **269**(1): p. 30-36.

39. Vermeulen, R.C. and H.R. Scholte, *Rupture of silicone gel breast implants and symptoms of pain and fatigue.* J Rheumatol, 2003. **30**(10): p. 2263-7.

40. Lee, I.M., et al., *Prospective cohort study of breast implants and the risk of connective-tissue diseases.* Int J Epidemiol, 2011. **40**(1): p. 230-8.

41. Singh, N., et al., *Five-Year Safety Data for More than 55,000 Subjects following Breast Implantation: Comparison of Rare Adverse Event Rates with Silicone Implants versus National Norms and Saline Implants.* Plast Reconstr Surg, 2017. **140**(4): p. 666-679.

42. Lipworth, L., L.R. Holmich, and J.K. McLaughlin, *Silicone breast implants and connective tissue disease: no association.* Semin Immunopathol, 2011. **33**(3): p. 287-94.

43. Berner, I., et al., *Comparative examination of complaints of patients with breast-cancer with and without silicone implants.* Eur J Obstet Gynecol Reprod Biol, 2002. **102**(1): p. 61-6.

44. Breiting, V.B., et al., *Long-term health status of Danish women with silicone breast implants.* Plast Reconstr Surg, 2004. **114**(1): p. 217-26; discussion 227-8.

45. Fryzek, J.P., et al., *Self-reported symptoms among women after cosmetic breast implant and breast reduction surgery.* Plast Reconstr Surg, 2001. **107**(1): p. 206-13.

46. Kjøller, K., et al., *Self-reported musculoskeletal symptoms among Danish women with cosmetic breast implants.* Ann Plast Surg, 2004. **52**(1): p. 1-7.

47. Brinton, L.A., et al., *Breast cancer following augmentation mammoplasty (United States).* Cancer Causes Control, 2000. **11**(9): p. 819-27.

48. Brinton, L.A., et al., *Cancer risk at sites other than the breast following augmentation mammoplasty.* Ann Epidemiol, 2001. **11**(4): p. 248-56.

49. Brisson, J., et al., *Cancer incidence in a cohort of Ontario and Quebec women having bilateral breast augmentation.* Int J Cancer, 2006. **118**(11): p. 2854-62.

50. Deapen, D., et al., *Breast cancer stage at diagnosis and survival among patients with prior breast implants.* Plast Reconstr Surg, 2000. **105**(2): p. 535-40.

51. Deapen, D.M., E.M. Hirsch, and G.S. Brody, *Cancer risk among Los Angeles women with cosmetic breast implants.* Plast Reconstr Surg, 2007. **119**(7): p. 1987-1992.

52. Friis, S., et al., *Cancer risk among Danish women with cosmetic breast implants.* Int J Cancer, 2006. **118**(4): p. 998-1003.

53. McLaughlin, J.K., et al., *Long-term cancer risk among Swedish women with cosmetic breast implants: an update of a nationwide study.* J Natl Cancer Inst, 2006. **98**(8): p. 557-60.

54. Mellemkjaer, L., et al., *Cancer occurrence after cosmetic breast implantation in Denmark.* Int J Cancer, 2000. **88**(2): p. 301-6.

55. Pukkala, E., et al., *Incidence of breast and other cancers among Finnish women with cosmetic breast implants, 1970-1999.* J Long Term Eff Med Implants, 2002. **12**(4): p. 271-9.

56. Noels, E.C., et al., *Breast implants and the risk of breast cancer: a meta-analysis of cohort studies.* Aesthet Surg J, 2015. **35**(1): p. 55-62.

57. Jakub, J.W., et al., *Breast cancer in patients with prior augmentation: presentation, stage, and lymphatic mapping.* Plast Reconstr Surg, 2004. **114**(7): p. 1737-42.

58. Miglioretti, D.L., et al., *Effect of breast augmentation on the accuracy of mammography and cancer characteristics.* JAMA, 2004. **291**(4): p. 442-50.

59. Siotos, C., et al., *Survival and Disease Recurrence Rates among Breast Cancer Patients following Mastectomy with or without Breast Reconstruction.* Plast Reconstr Surg, 2019. **144**(2): p. 169e-177e.

60. Lipworth, L., et al., *Cancer among Scandinavian women with cosmetic breast implants: a pooled long-term follow-up study.* Int J Cancer, 2009. **124**(2): p. 490-3.

61. Pan, S.Y., et al., *Canadian breast implant cohort: extended follow-up of cancer incidence.* Int J Cancer, 2012. **131**(7): p. E1148-57.

62. de Jong, D., et al., *Anaplastic large-cell lymphoma in women with breast implants.* JAMA, 2008. **300**(17): p. 2030-5.

63. Collett, D.J., et al., *Current Risk Estimate of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Textured Breast Implants.* Plast Reconstr Surg, 2019. **143**(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma): p. 30S-40S.

64. Magnusson, M., et al., *The Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand Confirms the Highest Risk for Grade 4 Surface Breast Implants.* Plast Reconstr Surg, 2019. **143**(5): p. 1285-1292.

65. Rastogi, P., et al., *Theories of Etiopathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma.* Plast Reconstr Surg, 2019. **143**(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma): p. 23S-29S.

66. US_FDA, *Medical device reports of breast implant-associated anaplastic large cell lymphoma.* https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm481899.htm, 2019. **Accessed 9 April 2019**.

67. Aladily, T.N., et al., *Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases.* Am J Surg Pathol, 2012. **36**(7): p. 1000-8.

68. Brody, G.S., *Anaplastic Large Cell Lymphoma Occurring in Women with Breast Implants: Analysis of 173 Cases.* Plast Reconstr Surg, 2015. **136**(4): p. 553e-554e.

69. Gidengil, C.A., et al., *Breast implant-associated anaplastic large cell lymphoma: a systematic review.* Plast Reconstr Surg, 2015. **135**(3): p. 713-720.

70. Hart, A.M., et al., *Breast Implant-Associated Anaplastic Large Cell Lymphoma: Report of 2 Cases and Review of the Literature.* Aesthet Surg J, 2014. **34**(6): p. 884-94.

71. Jewell, M., et al., *Anaplastic large T-cell lymphoma and breast implants: a review of the literature.* Plast Reconstr Surg, 2011. **128**(3): p. 651-661.

72. Kim, B., et al., *Anaplastic large cell lymphoma and breast implants: a systematic review.* Plast Reconstr Surg, 2011. **127**(6): p. 2141-2150.

73. Lazzeri, D., et al., *ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity.* Clin Breast Cancer, 2011. **11**(5): p. 283-96.

74. Leberfinger, A.N., et al., *Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review.* JAMA Surg, 2017. **152**(12): p. 1161-1168.

75. Loch-Wilkinson, A., et al., *Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk.* Plast Reconstr Surg, 2017. **140**(4): p. 645-654.

76. Locke, M.B. and J. Lofts, *Variable presentation of anaplastic large-cell lymphoma in patients with breast implants.* ANZ J Surg, 2017. **87**(10): p. 789-794.

77. Miranda, R.N., et al., *Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.* J Clin Oncol, 2014. **32**(2): p. 114-20.

78. Miranda, R.N., et al., *Anaplastic large cell lymphoma involving the breast: a clinicopathologic study of 6 cases and review of the literature.* Arch Pathol Lab Med, 2009. **133**(9): p. 1383-90.

79. Popplewell, L., et al., *Primary anaplastic large-cell lymphoma associated with breast implants.* Leuk Lymphoma, 2011. **52**(8): p. 1481-7.

80. Ramos-Gallardo, G., et al., *Breast Implant and Anaplastic Large Cell Lymphoma Meta-Analysis.* J Invest Surg, 2017. **30**(1): p. 56-65.

81. Ravi-Kumar, S., et al., *Anaplastic large cell lymphoma associated with breast implants.* World J Plast Surg, 2012. **1**(1): p. 30-5.





82. Roden, A.C., et al., *Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder.* Mod Pathol, 2008. **21**(4): p. 455-63.

83. Taylor, K.O., H.R. Webster, and H.M. Prince, *Anaplastic large cell lymphoma and breast implants: five Australian cases.* Plast Reconstr Surg, 2012. **129**(4): p. 610e-617e.

84. Thompson, P.A. and H.M. Prince, *Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis.* Curr Hematol Malig Rep, 2013. **8**(3): p. 196-210.

85. Xu, J. and S. Wei, *Breast implant-associated anaplastic large cell lymphoma: review of a distinct clinicopathologic entity.* Arch Pathol Lab Med, 2014. **138**(6): p. 842-6.

86. Ye, X., et al., *Anaplastic large cell lymphoma (ALCL) and breast implants: breaking down the evidence.* Mutat Res Rev Mutat Res, 2014. **762**: p. 123-32.

87. Wang, S.S., et al., *Breast implants and anaplastic large cell lymphomas among females in the California Teachers Study cohort.* Br J Haematol, 2016. **174**(3): p. 480-3.

88. Doren, E.L., et al., *U.S. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma.* Plast Reconstr Surg, 2017. **139**(5): p. 1042-1050.

89. de Boer, M., et al., *Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast.* JAMA Oncol, 2018. **4**(3): p. 335-341.

90. Largent, J., et al., *Risk of lymphoma in women with breast implants: analysis of clinical studies.* Eur J Cancer Prev, 2012. **21**(3): p. 274-80.

91. Vase, M., et al., *Breast implants and anaplastic large-cell lymphoma: a danish population-based cohort study.* Cancer Epidemiol Biomarkers Prev, 2013. **22**(11): p. 2126-9.

92. NCCN, *Clinical Practice Guidelines in Oncology, T-cell Lymphoma*. Guidelines Version 1.2021, NCCN.org.

93. Clemens, M.W., et al., *Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.* J Clin Oncol, 2016. **34**(2): p. 160-8.

94. Ebner, P.J., et al., *Breast implant-associated anaplastic large cell lymphoma, a systematic review and in-depth evaluation of the current understanding.* J Surg Oncol, 2019. **120**(4): p. 573-577.

95. Quesada, A.E., et al., *Breast implant-associated anaplastic large cell lymphoma: a review.* Mod Pathol, 2019. **32**(2): p. 166-188.

96. Winther, J.F., et al., *Neurological disease among women with silicone breast implants in Denmark.* Acta Neurol Scand, 2001. **103**(2): p. 93-6.

97. Ahern, M., et al., *Breast implants and illness: a model of psychological illness.* Ann Rheum Dis, 2002. **61**(7): p. 659.

98. Brinton, L.A., et al., *Mortality among augmentation mammoplasty patients.* Epidemiology, 2001. **12**(3): p. 321-6.

99. Jacobsen, P.H., et al., *Mortality and suicide among Danish women with cosmetic breast implants.* Arch Intern Med, 2004. **164**(22): p. 2450-5.

100. Koot, V.C., et al., *Total and cause specific mortality among Swedish women with cosmetic breast implants: prospective study.* BMJ, 2003. **326**(7388): p. 527-8.

101. Pukkala, E., et al., *Causes of death among Finnish women with cosmetic breast implants, 1971-2001.* Ann Plast Surg, 2003. **51**(4): p. 339-42; discussion 343-4.

102. Rubin, J.P., et al., *Health characteristics of postmenopausal women with breast implants.* Plast Reconstr Surg, 2010. **125**(3): p. 799-810.

103. Zuckerman, D.M., C.E. Kennedy, and M. Terplan, *Breast Implants, Self-Esteem, Quality of Life, and the Risk of Suicide.* Womens Health Issues, 2016. **26**(4): p. 361-5.

104. Lugowski, S.J., et al., *Analysis of silicon in human tissues with special reference to silicone breast implants.* J Trace Elem Med Biol, 2000. **14**(1): p. 31-42.

105. Filiciani, S., et al., *Cohort Study to Assess the Impact of Breast Implants on Breastfeeding.* Plast Reconstr Surg, 2016. **138**(6): p. 1152-1159.

106. Hedén, P., et al., *Long-term safety and effectiveness of style 410 highly cohesive silicone breast implants.* Aesthetic Plast Surg, 2009. **33**(3): p. 430-6; discussion 437-8.

107. Jewell, M.L., et al., *Lactation Outcomes in More Than 3500 Women Following Primary Augmentation: 5-Year Data From the Breast Implant Follow-Up Study.* Aesthet Surg J, 2019. **39**(8): p. 875-883.

108. Lund, H.G., et al., *Low Risk of Skin and Nipple Sensitivity and Lactation Issues After Primary Breast Augmentation with Form-Stable Silicone Implants: Follow-Up in 4927 Subjects.* Aesthet Surg J, 2016. **36**(6): p. 672-80.

109. Brown, S.L., et al., *Breast implant surveillance reports to the U.S. Food and Drug Administration: maternal-child health problems.* J Long Term Eff Med Implants, 2006. **16**(4): p. 281-90.

110. Kjøller, K., et al., *Health outcomes in offspring of Danish mothers with cosmetic breast implants.* Ann Plast Surg, 2002. **48**(3): p. 238-45.

111. Signorello, L.B., et al., *Offspring health risk after cosmetic breast implantation in Sweden.* Ann Plast Surg, 2001. **46**(3): p. 279-86.

112. Hemminki, E., et al., *Births and perinatal health of infants among women who have had silicone breast implantation in Finland, 1967-2000.* Acta Obstet Gynecol Scand, 2004. **83**(12): p. 1135-40.

113. Flassbeck, D., et al., *Determination of siloxanes, silicon, and platinum in tissues of women with silicone gel-filled implants.* Anal Bioanal Chem, 2003. **375**(3): p. 356-62.

114. Katzin, W.E., et al., *Pathology of lymph nodes from patients with breast implants: a histologic and spectroscopic evaluation.* Am J Surg Pathol, 2005. **29**(4): p. 506-11.

115. Klang, E., et al., *Association between Enlarged Axillary Lymph Nodes and Silicone Breast Implant Ruptures seen on Magnetic Resonance Imaging.* Isr Med Assoc J, 2016. **18**(12): p. 719-724.

116. Chandra, G., et al., *A convenient and novel route to bis(alkyne)platinum(0) and other platinum(0) complexes from Speier's hydrosilylation catalyst.* Organometallics, 1987(6): p. 191-2.

117. Lappert, M.F. and F.P.A. Scott, *The reaction pathway from Speier's to Karstedt's hydrosilylation catalyst.* Journal of Organometallic Chemistry, 1995. **492**(2): p. C11-C13.

118. Lewis, L.N., et al., *Mechanism of Formation of Platinum(0) Complexes Containing Silicon-Vinyl Ligands.* Organometallics, 1995. **14**(5): p. 2202-2213.

119. Stein, J., et al., *In Situ Determination of the Active Catalyst in Hydrosilylation Reactions Using Highly Reactive Pt(0) Catalyst Precursors.* Journal of the American Chemical Society, 1999. **121**(15): p. 3693-3703.

**Sientra**
3333 Michelson Drive, Suite 650
Irvine, CA 92612
Toll Free: 888.708.0808
sientra.com



DFU-0002 R6